LivaNova (LIVN) 10-Q 30 Oct 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2019	Oct. 28, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	001-37599
Entity Incorporation, State or Country Code	X0
Entity Tax Identification Number	98-1268150
Entity Address, Address Line One	20 Eastbourne Terrace
Entity Address, City or Town	London
Entity Address, Country	GB
Entity Address, Postal Zip Code	W2 6LG
Country Region	44
City Area Code	0
Local Phone Number	203 325-0660
Title of 12(b) Security	Ordinary Shares - £1.00 par value per share
Trading Symbol	LIVN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		48,400,468
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	LIVANOVA PLC
Entity Central Index Key	0001639691
Current Fiscal Year End Date	--12-31

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Net sales	$ 268,610	$ 272,082	$ 796,580	$ 809,978
Costs and expenses:
Cost of sales - exclusive of amortization	86,128	94,300	245,324	270,891
Product remediation	3,076	3,434	11,136	8,691
Selling, general and administrative	123,015	115,136	375,932	342,736
Research and development	45,904	42,417	124,023	108,384
Merger and integration expenses	6,716	12,659	14,345	20,028
Restructuring expenses	698	436	4,563	2,793
Impairment of intangible assets	0	0	50,295	0
Amortization of intangibles	11,146	9,457	29,690	28,075
Insurance recovery	(33,834)	0	(33,834)	0
Operating income (loss) from continuing operations	25,761	(5,757)	(24,894)	28,380
Interest income	151	184	624	863
Interest expense	(4,774)	(2,633)	(10,490)	(7,750)
Gain on acquisition	0	0	0	11,484
Foreign exchange and other gains (losses)	327	(727)	(795)	(1,070)
Income (loss) from continuing operations before tax	21,465	(8,933)	(35,555)	31,907
Income tax (benefit) expense	(10,653)	(2,660)	(23,431)	203
Losses from equity method investments	0	0	0	(627)
Net income (loss) from continuing operations	32,118	(6,273)	(12,124)	31,077
Net (loss) income from discontinued operations, net of tax	0	(904)	178	(9,915)
Net income (loss)	$ 32,118	$ (7,177)	$ (11,946)	$ 21,162
Basic income (loss) per share:
Continuing operations (in Dollars per Share)	$ 0.66	$ (0.13)	$ (0.25)	$ 0.64
Discontinued operations (in Dollars per Share)	0	(0.02)	0	(0.20)
Basic (loss) income per share (in Dollars per Share)	0.66	(0.15)	(0.25)	0.44
Diluted income (loss) per share:
Continuing operations (in Dollars per Share)	0.66	(0.13)	(0.25)	0.63
Discontinued operations (in Dollars per Share)	0	(0.02)	0	(0.20)
Diluted (loss) income per share (in Dollars per Share)	$ 0.66	$ (0.15)	$ (0.25)	$ 0.43
Shares used in computing basic (loss) income per share (in shares)	48,395	48,637	48,329	48,484
Shares used in computing diluted (loss) income per share (in shares)	48,820	48,637	48,329	49,427

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 32,118	$ (7,177)	$ (11,946)	$ 21,162
Other comprehensive (loss) income:
Net change in unrealized (loss) gain on derivatives	(870)	693	(665)	237
Tax effect	209	(168)	159	(57)
Net of tax	(661)	525	(506)	180
Foreign currency translation adjustment	(27,775)	1,863	(16,628)	(45,738)
Total other comprehensive (loss) income	(28,436)	2,388	(17,134)	(45,558)
Total comprehensive income (loss)	$ 3,682	$ (4,789)	$ (29,080)	$ (24,396)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 75,313	$ 47,204
Accounts receivable, net of allowance of $12,247 at September 30, 2019 and $11,598 at December 31, 2018	243,179	256,135
Inventories	167,756	153,535
Prepaid and refundable taxes	38,093	46,852
Prepaid expenses and other current assets	22,505	29,571
Total Current Assets	546,846	533,297
Property, plant and equipment, net	179,507	191,400
Goodwill	945,544	956,815
Intangible assets, net	699,493	770,439
Operating lease assets (Note 11)	54,283
Investments	24,942	24,823
Deferred tax assets	53,577	68,146
Other assets	5,749	4,781
Total Assets	2,509,941	2,549,701
Current Liabilities:
Current debt obligations	68,777	28,794
Accounts payable	75,522	76,735
Accrued liabilities and other	128,456	124,285
Current litigation provision liability	121,468	161,851
Taxes payable	10,128	22,530
Accrued employee compensation and related benefits	64,840	82,551
Total Current Liabilities	469,191	496,746
Long-term debt obligations	272,887	139,538
Contingent consideration	140,472	161,381
Litigation provision liability	31,500	132,210
Deferred tax liabilities	16,126	68,189
Long-term operating lease liabilities (Note 11)	44,724	0
Long-term employee compensation and related benefits	25,838	25,264
Other long-term liabilities	13,921	22,635
Total Liabilities	1,014,659	1,045,963
Commitments and contingencies (Note 12)
Stockholders’ Equity:
Ordinary Shares, £1.00 par value: unlimited shares authorized; 49,380,570 shares issued and 48,399,097 shares outstanding at September 30, 2019; 49,323,418 shares issued and 48,205,783 shares outstanding at December 31, 2018	76,217	76,144
Additional paid-in capital	1,725,482	1,705,111
Accumulated other comprehensive loss	(41,610)	(24,476)
Accumulated deficit	(263,525)	(251,579)
Treasury stock at cost, 981,473 ordinary shares at September 30, 2019; 1,117,635 ordinary shares at December 31, 2018	(1,282)	(1,462)
Total Stockholders’ Equity	1,495,282	1,503,738
Total Liabilities and Stockholders’ Equity	$ 2,509,941	$ 2,549,701

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) $ in Thousands	Sep. 30, 2019USD ($)shares	Sep. 30, 2019£ / shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2018£ / shares
Statement of Financial Position [Abstract]
Allowance for doubtful trade receivables | $	$ 12,247		$ 11,598
Ordinary shares, par value (in Pounds per Share) | £ / shares		£ 1		£ 1
Ordinary shares issued (in shares)	49,380,570		49,323,418
Ordinary shares outstanding (in shares)	48,399,097		48,205,783
Treasury stock (in shares)	981,473		1,117,635

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating Activities:
Net income (loss)	$ (11,946)	$ 21,162
Non-cash items included in net (loss) income:
Impairment of intangible assets	50,295	0
Amortization	29,690	28,052
Deferred tax benefit	(26,422)	(13,488)
Stock-based compensation	24,127	21,387
Depreciation	23,115	24,979
Amortization of operating lease assets	8,961
Amortization of income taxes payable on intercompany transfers of property	3,261	4,155
Gain on acquisition	0	(11,484)
Other	1,952	453
Changes in operating assets and liabilities:
Accounts receivable, net	5,433	30,506
Inventories	(18,181)	(7,622)
Other current and non-current assets	6,627	(16,757)
Accounts payable and accrued current and non-current liabilities	(28,964)	12,895
Taxes payable	(14,367)	4,993
Litigation provision liability	(140,823)	0
Restructuring reserve	(6,766)	368
Net cash (used in) provided by operating activities	(94,008)	99,599
Investing Activities:
Purchases of property, plant and equipment	(16,801)	(24,318)
Acquisitions, net of cash acquired	(10,750)	(279,863)
Purchases of intangible assets	(3,186)	(781)
Proceeds from asset sales	505	13,872
Purchase of investment	(287)	(3,000)
Proceeds from the sale of CRM business franchise, net of cash disposed	0	186,682
Net cash used in investing activities	(30,519)	(107,408)
Financing Activities:
Proceeds from long-term debt obligations	193,490	60,000
Payment of contingent consideration	(17,989)	(651)
Repayment of long-term debt obligations	(12,330)	(12,290)
Shares repurchased from employees for minimum tax withholding	(6,183)	(8,559)
Debt issuance costs	(3,795)	0
Proceeds from share issuances under ESPP	2,574	0
Change in short-term borrowing, net	(2,173)	(31,281)
Proceeds from exercise of stock options	331	4,177
Proceeds from short-term borrowing (maturities greater than 90 days)	0	240,000
Repayment of short-term borrowing (maturities greater than 90 days)	0	(240,000)
Payment of deferred consideration - acquisition of Caisson Interventional, LLC	0	(14,073)
Other	(184)	(233)
Net cash provided by (used in) financing activities	153,741	(2,910)
Effect of exchange rate changes on cash and cash equivalents	(1,105)	(2,948)
Net increase (decrease) in cash and cash equivalents	28,109	(13,667)
Cash and cash equivalents at beginning of period	47,204	93,615
Cash and cash equivalents at end of period	$ 75,313	$ 79,948

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Unaudited Condensed Consolidated Financial Statements	Note 1. Unaudited Condensed Consolidated Financial Statements Basis of Presentation The accompanying condensed consolidated financial statements of LivaNova as of, and for the three and nine months ended September 30, 2019 and 2018 , have been prepared in accordance with U.S. GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying condensed consolidated balance sheet of LivaNova at December 31, 2018 has been derived from audited financial statements contained in our 2018 Form 10-K, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair statement of the operating results of LivaNova and its subsidiaries, for the three and nine months ended September 30, 2019 , and are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 . The financial information presented herein should be read in conjunction with the audited consolidated financial statements and notes thereto accompanying our 2018 Form 10-K. Reclassifications We have reclassified certain prior period amounts for comparative purposes. These reclassifications did not have a material effect on our financial condition, results of operations or cash flows. Gross profit, as previously presented for the nine months ended September 30, 2018 , excluded amortization of certain intangible assets. For the nine months ended September 30, 2018 , $10.7 million of such amortization expense should have been included in cost of sales. The Company has determined that this misclassification error was not material to any prior annual or interim periods. For comparability among periods, the Company no longer presents gross profit within its condensed consolidated statements of income (loss). Significant Accounting Policies Our significant accounting policies are detailed in “Note 2. Basis of Presentation, Use of Accounting Estimates and Significant Accounting Policies” and “Note 3. Revenue Recognition” of our 2018 Form 10-K. Changes to our accounting policies as a result of adopting the new lease accounting standard are discussed below. On January 1, 2019, we adopted ASC Update (“ASU”) No 2016-02, Leases , including subsequent related accounting updates (collectively referred to as “Topic 842”), which supersedes the previous accounting model for leases. We adopted the standard using the modified retrospective approach with an effective date as of January 1, 2019. Prior year financial statements were not recast under the new standard. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward our historical assessment of whether contracts are or contain leases and lease classification. We also elected the practical expedient to account for lease and non-lease components together as a single combined lease component, which is applicable to all asset classes. We did not, however, elect the practical expedient related to using hindsight in determining the lease term as this was not relevant following our election of the modified retrospective approach. In addition, we elect certain practical expedients on an ongoing basis, including the practical expedient for short-term leases pursuant to which a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize a lease liability and operating lease asset for leases with a term of 12 months or less and that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. We have applied this accounting policy to all asset classes in our portfolio and will recognize the lease payments for such short-term leases within profit and loss on a straight-line basis over the lease term. Furthermore, from a lessor perspective, certain of our agreements that allow the customer to use, rather than purchase, our medical devices will meet the criteria of being a lease in accordance with the new standard. While the amount of revenue and expenses recognized over the contract term will not be impacted, the timing of revenue and expense recognition will be impacted depending upon lease classification. We enacted appropriate changes to our business processes, systems and internal controls to support identification, recognition and disclosure of leases under the new standard. We determine if an arrangement is or contains a lease at inception. Operating lease assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the latter of our lease standard effective date for adoption or the lease commencement date. Variable lease payments, such as common area rent maintenance charges and rent escalations not known upon lease commencement, are not included in determination of the minimum lease payments and will be expensed in the period in which the obligation for those payments is incurred. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement in determining the present value of future payments. The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. We used the incremental borrowing rate available nearest to our adoption date for leases that commenced prior to that date. The operating lease asset also includes any lease payments made in advance and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For additional information refer to “ Note 11. Leases

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Business Combinations	Note 2. Business Combinations Miami Instruments On June 12, 2019, we acquired the minimally invasive cardiac surgery instruments business from Miami Instruments, LLC (“Miami Instruments”) for cash consideration of up to $17.0 million . The related operations have been integrated into our Cardiovascular business franchise as part of our Heart Valves portfolio. Cash of $10.8 million was paid at closing with up to $6.0 million in contingent consideration based on achieving certain milestones. In connection with this acquisition, we recognized $14.7 million in developed technology and in-process research and development (“IPR&D”) intangible assets and $1.5 million

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 3. Discontinued Operations In November 2017, we concluded that the sale of our Cardiac Rhythm Management (“CRM”) business franchise represented a strategic shift in our business that would have a major effect on future operations and financial results. Accordingly, the operating results of CRM are classified as discontinued operations on our condensed consolidated statements of income (loss) for all the periods presented in this Quarterly Report on Form 10-Q. We completed the CRM Sale on April 30, 2018 to MicroPort Cardiac Rhythm B.V. and MicroPort Scientific Corporation for total cash proceeds of $195.9 million , less cash transferred of $9.2 million , subject to a closing working capital adjustment. In conjunction with the sale, we entered into transition services agreements to provide certain support services generally for up to twelve months from the closing date of the sale. The services include, among others, accounting, information technology, human resources, quality assurance, regulatory affairs, supply chain, clinical affairs and customer support. For providing these services, during three and nine months ended September 30, 2019 , we recognized income of $0.1 million and $0.9 million , respectively, and during the three and nine months ended September 30, 2018, we recognized income of $1.1 million and $2.0 million , respectively. Income recognized related to the transition services agreements is recorded as a reduction to the related expenses in the associated expense line items in the condensed consolidated statements of income (loss). The following table represents the financial results of CRM presented as net (loss) income from discontinued operations in the condensed consolidated statements of income (loss) (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net sales $ — $ — $ — $ 77,366 Costs and expenses: Cost of sales — — (43 ) 27,306 Selling, general and administrative expenses — 543 26 43,441 Research and development — — (161 ) 16,577 Restructuring expenses — — — 651 Revaluation gain on assets and liabilities held for sale — — — (1,213 ) Loss on sale of CRM — — — 214 Operating (loss) income from discontinued operations — (543 ) 178 (9,610 ) Foreign exchange and other gains — — — 102 (Loss) income from discontinued operations, before tax — (543 ) 178 (9,508 ) Income tax expense (benefit) — 361 — (804 ) Losses from equity method investments — — — (1,211 ) Net (loss) income from discontinued operations $ — $ (904 ) $ 178 $ (9,915 ) Cash flows attributable to our discontinued operations are included in our condensed consolidated statements of cash flows. For the nine months ended September 30, 2018 , CRM’s capital expenditures were $0.9 million and stock-based compensation expense was $2.1 million

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Restructuring	Note 4. Restructuring We initiate restructuring plans to leverage economies of scale, streamline distribution and logistics and strengthen operational and administrative effectiveness in order to reduce overall costs. Costs associated with these plans were reported as restructuring expenses in the operating results of our condensed consolidated statements of income (loss). Our 2015 and 2016 Reorganization Plans (the “Prior Plans”) were initiated October 2015 and March 2016, respectively, in conjunction with the completion of the merger of Cyberonics, Inc. and Sorin S.p.A. in October 2015. The Prior Plans include the closure of the R&D facility in Meylan, France and consolidation of its R&D capabilities into the Clamart, France facility. We completed the Prior Plans during 2018. In December 2018, we initiated a reorganization plan (the “2018 Plan”) in order to reduce manufacturing and operational costs associated with our Cardiovascular facilities in Saluggia and Mirandola, Italy and Arvada, Colorado. We estimate that the 2018 Plan will result in a net reduction of approximately 75 personnel and is expected to be completed by the end of 2019. The following table presents the accruals, inventory obsolescence and other reserves, recorded in connection with our reorganization plans (in thousands): Employee Severance and Other Termination Costs Other Total Balance at December 31, 2018 $ 10,195 $ 3,069 $ 13,264 Charges 4,488 75 4,563 Cash payments and other (13,147 ) (2,059 ) (15,206 ) Balance at September 30, 2019 (1) $ 1,536 $ 1,085 $ 2,621 (1) Cumulatively, we have recognized a total of $103.8 million in restructuring expense inclusive of discontinued operations under the Prior Plans and the 2018 Plan. The following table presents restructuring expense by reportable segment (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Cardiovascular $ 783 $ 354 $ 1,521 $ 2,093 Neuromodulation (171 ) 17 314 34 Other 86 65 2,728 666 Total $ 698 $ 436 $ 4,563 $ 2,793

Product Remediation Liability

Product Remediation Liability	9 Months Ended
	Sep. 30, 2019
Product Remediation [Abstract]
Product Remediation Liability	Note 5. Product Remediation Liability On December 29, 2015, we received an FDA Warning Letter (the “Warning Letter”) alleging certain violations of FDA regulations applicable to medical device manufacturing at our Munich, Germany and Arvada, Colorado facilities. On October 13, 2016, the CDC and FDA separately released safety notifications regarding 3T Heater-Cooler devices in response to which we issued a Field Safety Notice Update for U.S. users of our 3T Heater-Cooler devices to proactively and voluntarily contact facilities to facilitate implementation of the CDC and FDA recommendations. At December 31, 2016, we recognized a liability for a product remediation plan related to our 3T Heater-Cooler device (“3T device”). The remediation plan we developed consists primarily of a modification of the 3T device design to include internal sealing and the addition of a vacuum system to new and existing devices. These changes are intended to address regulatory actions and to reduce further the risk of possible dispersion of aerosols from 3T devices in the operating room. We concluded that it was probable that a liability had been incurred upon management’s approval of the plan and the commitments made by management to various regulatory authorities globally in November and December 2016, and furthermore, the cost associated with the plan was reasonably estimable. The deployment of this solution for commercially distributed devices has been dependent upon final validation and verification of the design changes and approval or clearance by regulatory authorities worldwide, including FDA clearance in the U.S. It is reasonably possible that our estimate of the remediation liability could materially change in future periods due to the various significant assumptions involved such as customer behavior, market reaction and the timing of approvals or clearance by regulatory authorities worldwide. In April 2017, we obtained CE Mark in Europe for the design change of the 3T device, and in May 2017 we completed our first vacuum canister and internal sealing upgrade on a customer-owned device. We are currently implementing the vacuum canister and internal sealing upgrade program in as many countries as possible until all devices are upgraded. On October 11, 2018, after review of information provided by us, the FDA concluded that we could commence the vacuum canister and internal sealing upgrade program in the U.S. As part of the remediation plan, we continue to offer a no-charge deep disinfection service (deep cleaning service) for 3T device users as we receive the required regulatory approvals. The deep disinfection service was rolled out in Europe in the second half of 2015, and on April 12, 2018, the FDA agreed to allow us to move forward with the deep cleaning service in the U.S., thereby adding to the growing list of countries around the world in which we offer this service. Also, we are continuing to offer the loaner program for 3T devices, initiated in the fourth quarter of 2016, to provide existing 3T device users with a new loaner 3T device at no charge pending regulatory approval and implementation of the vacuum system addition and deep disinfection service worldwide. This loaner program began in the U.S., was rolled out in Europe shortly thereafter, and is being made available progressively on a global basis, prioritizing and allocating devices to 3T device users based on pre-established criteria. Changes in the carrying amount of the product remediation liability are as follows (in thousands): Balance at December 31, 2018 $ 14,745 Adjustments 2,567 Remediation activity (9,341 ) Effect of changes in foreign currency exchange rates (527 ) Balance at September 30, 2019 (1) $ 7,444 (1) At September 30, 2019 , the product remediation liability balance is included within accrued liabilities and other on the condensed consolidated balance sheet. We recognized product remediation expenses during the three and nine months ended September 30, 2019 , of $3.1 million and $11.1 million , respectively, and $3.4 million and $8.7 million , respectively, during the three and nine months ended September 30, 2018 . Product remediation expenses include internal labor costs, costs to remediate certain inspectional observations made by the FDA at our Munich facility and costs associated with the incorporation of the modification of the 3T device design into the next generation 3T device. These costs and related legal costs are expensed as incurred and are not included within the product remediation liability presented above. At September 30, 2019 , our balance sheet includes a $153.0 million provision related to litigation involving our 3T device. For further information, please refer to “ Note 12. Commitments and Contingencies .”

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 6. Intangible Assets Intangible Asset Impairment During the second quarter of 2019, we determined that there would be a delay in the estimated commercialization date of the Company’s obstructive sleep apnea product currently under development. This delay constituted a triggering event that required evaluation of the IPR&D asset arising from the ImThera Medical Inc. (“ImThera”) acquisition for impairment. Based on the assessment performed, we determined that the IPR&D asset was impaired and as a result, recorded an impairment of $50.3 million , which is included in our Neuromodulation segment. The carrying value of the IPR&D asset as of September 30, 2019 is $112.0 million . The estimated fair value of IPR&D was determined using the income approach. Future delays in commercialization or changes in management estimates could result in further impairment. Intangible Asset Reclassification During the third quarter of 2019, upon receiving FDA approval of the LifeSPARC system, we reclassified IPR&D assets of $107.5 million from the acquisition of CardiacAssist, Inc., doing business as TandemLife (“TandemLife”) to finite-lived developed technology intangible assets and began amortizing the intangible asset over a useful life of 15 years

Investments

Investments	9 Months Ended
	Sep. 30, 2019
Investments [Abstract]
Investments	Note 7. Investments The following table details the carrying value of our investments in equity securities of non-consolidated affiliates without readily determinable fair values for which we do not exert significant influence over the investee. These equity investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. These equity investments are included in investments on the condensed consolidated balance sheets (in thousands): Equity Investments Without Readily Determinable Fair Values September 30, 2019 December 31, 2018 Respicardia Inc. (1) $ 17,706 $ 17,706 Ceribell, Inc. 3,000 3,000 Rainbow Medical Ltd. 1,067 1,119 MD Start II 1,090 1,144 Highlife S.A.S. 1,034 1,084 Other 770 770 24,667 24,823 Equity method investments (2) 275 — $ 24,942 $ 24,823 (1) Respicardia Inc. (“Respicardia”) is a privately funded U.S. company developing an implantable device designed to restore a more natural breathing pattern during sleep in patients with central sleep apnea by transvenously stimulating the phrenic nerve. We have a loan outstanding to Respicardia, with a carrying amount of $0.6 million as of September 30, 2019 and December 31, 2018 , which is included in prepaid expenses and other current assets in the condensed consolidated balance sheet. (2) During the second quarter of 2019, we invested in equity securities that we account for under the equity method of accounting due to our deemed ability to exercise significant influence. We initially invested $0.3 million and are required to fund up to a total of approximately €5.0 million (approximately $5.5 million as of September 30, 2019 ) based on cash calls.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8. Fair Value Measurements We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers between Level 1, Level 2, or Level 3 during the nine months ended September 30, 2019 and 2018 . Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands): Fair Value as of September 30, 2019 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - freestanding instruments (FX) $ 1,213 $ — $ 1,213 $ — $ 1,213 $ — $ 1,213 $ — Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 1,458 $ — $ 1,458 $ — Derivative liabilities - designated as cash flow hedges (interest rate swaps) 519 — 519 — Derivative liabilities - freestanding instruments (FX) 1,869 — 1,869 — Contingent consideration (1) 165,274 — — 165,274 $ 169,120 $ — $ 3,846 $ 165,274 Fair Value as of December 31, 2018 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - freestanding instruments (FX) $ 236 $ — $ 236 $ — $ 236 $ — $ 236 $ — Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 1,354 $ — $ 1,354 $ — Derivative liabilities - designated as cash flow hedges (interest rate swaps) 865 — 865 — Derivative liabilities - freestanding instruments (FX) 3,173 — 3,173 — Contingent consideration (1) 179,911 — — 179,911 $ 185,303 $ — $ 5,392 $ 179,911 (1) The contingent consideration liability represents contingent payments primarily related to five completed acquisitions, including: Inversiones Drilltex SAS (“Drilltex”), Caisson, ImThera, TandemLife and Miami Instruments. See the table below for additional information. Our recurring fair value measurements, using significant unobservable inputs (Level 3), relate solely to our contingent consideration liability. The following table provides a reconciliation of the beginning and ending balance of the contingent consideration liability (in thousands): Total contingent consideration liability at December 31, 2018 $ 179,911 Additions (1) 7,184 Payments (2) (19,234 ) Changes in fair value (3) (4) (2,425 ) Effect of changes in foreign currency exchange rates (162 ) Total contingent consideration liability at September 30, 2019 165,274 Less current portion of contingent consideration liability at September 30, 2019 24,802 Long-term portion of contingent consideration liability at September 30, 2019 $ 140,472 (1) See “ Note 2. Business Combinations ” for additional discussion. (2) In July 2019, we achieved a regulatory milestone upon receiving FDA approval of the LifeSPARC system, triggering the payment of $19.0 million during the third quarter of 2019 to settle the related contingent consideration liability in connection with our TandemLife acquisition. The probability of additional payments and projected years of payment for the remaining regulatory milestones, as outlined in our TandemLife acquisition, remain unchanged. (3) The change in fair value includes a decrease of $17.8 million that was recognized during the second quarter of 2019 primarily due to the delay in timing of anticipated regulatory approval and commercialization for ImThera. While the probability of payment remains unchanged from the time of acquisition, the projected years of payment for the regulatory milestone-based payment and the sales-based earnout have been updated to occur between 2023-2024 and 2024-2028, respectively. See “ Note 6. Intangible Assets ” for additional discussion. This decrease was largely offset by impacts from the change in interest rates and the passage of time subsequent to December 31, 2018. (4) During the nine months ended September 30, 2019 , the change in fair value resulted in a decrease of $0.9 million and $1.5 million recorded to cost of sales - exclusive of amortization and research and development, respectively.

Financing Arrangements

Financing Arrangements	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Financing Arrangements	Note 9. Financing Arrangements The outstanding principal amount of long-term debt (in thousands, except interest rates): September 30, 2019 December 31, 2018 Maturity Interest Rate 2019 Debt Facility (1) $ 182,434 $ — March 2022 1.40% - 3.72% 2017 European Investment Bank (2) 103,570 103,570 June 2026 3.47% - 3.53% 2014 European Investment Bank (3) 36,317 47,606 June 2021 0.98% Mediocredito Italiano 6,674 7,623 December 2023 0.50% - 2.86% Bank of America Merrill Lynch Banco Múltiplo S.A. 4,898 — July 2021 8.47% Bank of America, U.S. 1,999 — January 2021 4.51% Banca del Mezzogiorno 1,304 2,718 December 2019 0.50% - 2.91% Other 1,375 1,324 Total long-term facilities 338,571 162,841 Less current portion of long-term debt 65,684 23,303 Total long-term debt $ 272,887 $ 139,538 (1) The facility agreement with Bank of America Merrill Lynch International DAC, Barclays Bank PLC, BNP Paribas (London Branch) and Intesa Sanpaolo S.P.A. provides a multicurrency term loan facility in an aggregate amount of $350 million and terminates on March 26, 2022 (the “2019 Debt Facility”). Principal repayments of 20% of the outstanding borrowings under the 2019 Debt Facility are due in September 2020, March 2021 and September 2021, with the remainder of the outstanding borrowings due in March 2022. (2) The 2017 European Investment Bank (“2017 EIB”) loan was obtained to support certain product development projects. The interest rate for the 2017 EIB loan is reset by the lender each principal payment date based on LIBOR. Interest payments are paid quarterly and principal payments are paid semi-annually. (3) The 2014 European Investment Bank (“2014 EIB”) loan was obtained in July 2014 to support certain product development projects. The interest rate for the 2014 EIB loan is reset by the lender each quarter based on the Euribor. Interest payments are paid quarterly and principal payments are paid semi-annually. On March 26, 2019, we entered into the 2019 Debt Facility. Borrowings under the facility bear interest at a rate of LIBOR plus 1.6% for borrowings in U.S. dollars and EURIBOR plus 1.4% for Euro-denominated borrowings. Proceeds from the facility are used for general corporate and working capital purposes, excluding acquisitions, dividends and share buybacks. Available borrowings under the 2019 Debt Facility commenced on March 26, 2019 and extend through March 26, 2020. Principal repayments of 20% of the outstanding borrowings under the 2019 Debt Facility are due in September 2020, March 2021 and September 2021, with the remainder of the outstanding borrowings due in March 2022. The 2019 Debt Facility contains financial covenants that require LivaNova to maintain a maximum consolidated net debt to EBITDA ratio, a minimum interest coverage ratio and a maximum consolidated net debt to net worth ratio. LivaNova must also maintain a minimum amount of consolidated net worth. The 2019 Debt Facility also contains customary representations and warranties, covenants, and events of default. At September 30, 2019 , LivaNova was in compliance with all covenants. On July 25, 2019, we entered into a €40.0 million (approximately $43.6 million as of September 30, 2019 ) credit facility agreement with Banca Nazionale del Lavoro SpA (“2019 Revolving Credit Facility”) for working capital needs. The 2019 Revolving Credit Facility has a term of two years and borrowings bear interest at Euribor plus 0.8% . Borrowings under the 2019 Revolving Credit Facility were zero at September 30, 2019 . Revolving Credit The outstanding principal amount of our short-term unsecured revolving credit agreements and other agreements with various banks was $3.1 million and $5.5 million , at September 30, 2019 and December 31, 2018 , respectively, with interest rates ranging from 8.50% to 8.69% and loan terms ranging from ten days to 210 days , as of September 30, 2019 .

Derivatives and Risk Management

Derivatives and Risk Management	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Risk Management	Note 10. Derivatives and Risk Management Due to the global nature of our operations, we are exposed to foreign currency exchange rate fluctuations. In addition, due to certain loans with floating interest rates, we are also subject to the impact of changes in interest rates on our interest payments. We enter into foreign currency exchange rate (“FX”) derivative contracts and interest rate swap contracts to reduce the impact of foreign currency exchange rate and interest rate fluctuations on earnings and cash flow. We measure all outstanding derivatives each period end at fair value and report the fair value as either financial assets or liabilities on the condensed consolidated balance sheets. We do not enter into derivative contracts for speculative purposes. At inception of the contract, the derivative is designated as either a freestanding derivative or a hedge. Derivatives that are not designated as hedging instruments are referred to as freestanding derivatives with changes in fair value included in earnings. If the derivative qualifies for hedge accounting, changes in the fair value of the derivative will be recorded in accumulated other comprehensive income (“AOCI”) until the hedged item is recognized in earnings upon settlement/termination. FX derivative gains and losses in AOCI are reclassified to our condensed consolidated statements of income (loss) as shown in the tables below and interest rate swap gains and losses in AOCI are reclassified to interest expense on our condensed consolidated statements of income (loss). We evaluate hedge effectiveness at inception and on an ongoing basis. If a derivative is no longer expected to be highly effective, hedge accounting is discontinued and the gains or losses are reclassified into earnings. Cash flows from derivative contracts are reported as operating activities on our condensed consolidated statements of cash flows. Freestanding FX Derivative Contracts The gross notional amount of FX derivative contracts, not designated as hedging instruments, outstanding at September 30, 2019 and December 31, 2018 was $273.1 million and $320.2 million , respectively. These derivative contracts are designed to offset the FX effects in earnings of various intercompany loans, our 2014 EIB loan, the Euro-denominated borrowings under the 2019 Debt Facility and trade receivables. We recorded net gains for these freestanding derivatives of $3.1 million and $5.6 million for the three months ended September 30, 2019 and 2018 , respectively, and net gains (losses) of $6.8 million and $(6.0) million for the nine months ended September 30, 2019 and 2018 , respectively. These gains and (losses) are included in foreign exchange and other gains (losses) on our condensed consolidated statements of income (loss). Cash Flow Hedges Notional amounts of open derivative contracts designated as cash flow hedges (in thousands): Description of Derivative Contract September 30, 2019 December 31, 2018 FX derivative contracts to be exchanged for British Pounds $ 8,185 $ 9,629 FX derivative contracts to be exchanged for Japanese Yen 26,462 23,985 FX derivative contracts to be exchanged for Canadian Dollars 1,532 7,637 FX derivative contracts to be exchanged for Euros 29,563 29,768 Interest rate swap contracts 29,072 38,115 $ 94,814 $ 109,134 After-tax net loss associated with derivatives designated as cash flow hedges recorded in the ending balance of AOCI and the amount expected to be reclassified to earnings in the next twelve months (in thousands): Description of Derivative Contract After-Tax Net Loss in AOCI as of September 30, 2019 Amount Expected to be Reclassified to Earnings in Next 12 Months FX derivative contracts $ (1,313 ) $ (1,313 ) Interest rate swap contracts (137 ) (78 ) $ (1,450 ) $ (1,391 ) Pre-tax gains (losses) for derivative contracts designated as cash flow hedges recognized in other comprehensive income (loss) (“OCI”) and the amount reclassified to earnings from AOCI (in thousands): Three Months Ended September 30, 2019 2018 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Losses Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings Gains Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other (losses) gains $ (689 ) $ 963 $ 125 $ 2,511 FX derivative contracts SG&A — (742 ) — (3,007 ) Interest rate swap contracts Interest expense — (40 ) — (72 ) $ (689 ) $ 181 $ 125 $ (568 ) Nine Months Ended September 30, 2019 2018 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Gains Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings Gains Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other gains (losses) $ 933 $ 3,094 $ 314 $ 1,999 FX derivative contracts SG&A — (1,470 ) — (1,833 ) Interest rate swap contracts Interest expense — (26 ) — (89 ) $ 933 $ 1,598 $ 314 $ 77 We offset fair value amounts associated with our derivative instruments on our condensed consolidated balance sheets that are executed with the same counterparty under master netting arrangements. Our netting arrangements include a right to set off or net together purchases and sales of similar products in the settlement process. The following tables present the fair value and the location of derivative contracts reported in the condensed consolidated balance sheets (in thousands): September 30, 2019 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) Interest rate swap contracts Accrued liabilities $ 385 Interest rate swap contracts Other long-term liabilities 134 FX derivative contracts Accrued liabilities 1,201 FX derivative contracts Prepaid expenses and other current assets 257 Total derivatives designated as hedging instruments 1,977 Derivatives Not Designated as Hedging Instruments FX derivative contracts Prepaid expenses and other current assets $ 1,213 Accrued liabilities 1,869 Total derivatives not designated as hedging instruments 1,213 1,869 Total derivatives $ 1,213 $ 3,846 December 31, 2018 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) Interest rate swap contracts Accrued liabilities $ 536 Interest rate swap contracts Other long-term liabilities 329 FX derivative contracts Accrued liabilities 1,354 Total derivatives designated as hedging instruments 2,219 Derivatives Not Designated as Hedging Instruments FX derivative contracts Prepaid expenses and other current assets $ 236 Accrued liabilities 3,173 Total derivatives not designated as hedging instruments 236 3,173 Total derivatives $ 236 $ 5,392 (1) For the classification of inputs used to evaluate the fair value of our derivatives, refer to “ Note 8. Fair Value Measurements .”

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	Note 11. Leases We have operating leases primarily for (i) office space, (ii) manufacturing, warehouse and research and development facilities and (iii) vehicles. Our leases have remaining lease terms up to 12 years, some of which include options to extend the leases, and some of which include options to terminate the leases at our sole discretion. The components of operating lease assets, liabilities and costs are as follows (in thousands): Operating Lease Assets and Liabilities September 30, 2019 Assets Operating lease right-of-use assets $ 54,283 Liabilities Accrued liabilities and other $ 10,565 Long-term operating lease liabilities 44,724 Total lease liabilities $ 55,289 Operating Lease Cost Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Operating lease cost $ 3,391 $ 10,600 Variable lease cost 225 651 Short-term lease cost 258 538 Total lease cost $ 3,874 $ 11,789 Contractual maturities of our lease liabilities as of September 30, 2019 , are as follows (in thousands): Remaining 2019 $ 2,728 2020 11,309 2021 9,411 2022 8,263 2023 6,913 Thereafter 21,866 Total lease payments 60,490 Less: Amount representing interest 5,201 Present value of lease liabilities $ 55,289 Lease Term and Discount Rate September 30, 2019 Weighted Average Remaining Lease Term (in years) 7.3 Weighted Average Discount Rate 2.3 % Other Information (in thousands) Nine Months Ended September 30, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 10,111 Operating lease assets obtained in exchange for lease liabilities $ 5,403 Disclosures Related to Periods Prior to Adoption of Topic 842 On January 1, 2019, we adopted Topic 842 using the modified retrospective adoption approach, as noted in “ Note 1. Unaudited Condensed Consolidated Financial Statements .” As required and as previously disclosed in our 2018 Form 10-K, the following table summarizes our future minimum operating lease payments as of December 31, 2018 (in thousands): Less than one year $ 11,986 One to three years 21,031 Three to five years 14,998 Thereafter 20,943 Total $ 68,958

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies FDA Warning Letter On December 29, 2015, the FDA issued a Warning Letter alleging certain violations of FDA regulations applicable to medical device manufacturers at our Munich, Germany and Arvada, Colorado facilities. The FDA inspected the Munich facility from August 24, 2015 to August 27, 2015 and the Arvada facility from August 24, 2015 to September 1, 2015. On August 27, 2015, the FDA issued a Form 483 identifying two observed non-conformities with certain regulatory requirements at the Munich facility. We did not receive a Form 483 in connection with the FDA’s inspection of the Arvada facility. Following the receipt of the Form 483, we provided written responses to the FDA describing corrective and preventive actions that were underway or to be taken to address the FDA’s observations at the Munich facility. The Warning Letter responded in part to our responses and identified other alleged violations related to the manufacture of our 3T Heater-Cooler device that were not previously included in the Form 483. The Warning Letter further stated that our 3T devices and other devices we manufactured at our Munich facility are subject to refusal of admission into the U.S. until resolution of the issues set forth by the FDA in the Warning Letter. The FDA has informed us that the import alert is limited to the 3T devices, but that the agency reserves the right to expand the scope of the import alert if future circumstances warrant such action. The Warning Letter did not request that existing users cease using the 3T device, and manufacturing and shipment of all of our products other than the 3T device remain unaffected by the import limitation. To help clarify these issues for current customers, we issued an informational Customer Letter in January 2016 and that same month agreed with the FDA on a process for shipping 3T devices to existing U.S. users pursuant to a certificate of medical necessity program. Finally, the Warning Letter stated that premarket approval applications for Class III devices to which certain Quality System regulation deviations identified in the Warning Letter are reasonably related will not be approved until the violations have been corrected; however, this restriction applies only to the Munich and Arvada facilities, which do not manufacture or design devices subject to Class III premarket approval. We continue to work diligently to remediate the FDA’s inspectional observations for the Munich facility, as well as the additional issues identified in the Warning Letter. We take these matters seriously and intend to respond timely and fully to the FDA’s requests. CDC and FDA Safety Communications and Company Field Safety Notice On October 13, 2016, the CDC and the FDA separately released safety notifications regarding the 3T devices. The CDC’s Morbidity and Mortality Weekly Report (“MMWR”) and Health Advisory Notice (“HAN”) reported that tests conducted by the CDC and its affiliates indicate that there appears to be genetic similarity between both patient and 3T device strains of the non-tuberculous mycobacterium (“NTM”) bacteria M. chimaera isolated in hospitals in Iowa and Pennsylvania. Citing the geographic separation between the two hospitals referenced in the investigation, the report asserts that 3T devices manufactured prior to August 18, 2014 could have been contaminated during the manufacturing process. The CDC’s HAN and FDA’s Safety Communication, issued contemporaneously with the MMWR report, each assess certain risks associated with 3T devices and provide guidance for providers and patients. The CDC notification states that the decision to use the 3T device during a surgical operation is to be taken by the surgeon based on a risk approach and on patient need. Both the CDC’s and FDA’s communications confirm that 3T devices are critical medical devices and enable doctors to perform life-saving cardiac surgery procedures. Also on October 13, 2016, concurrent with the CDC’s HAN and FDA’s Safety Communication, we issued a Field Safety Notice Update for U.S. users of 3T devices to proactively and voluntarily contact facilities to aid in implementation of the CDC and FDA recommendations. In the fourth quarter of 2016, we initiated a program to provide existing 3T device users with a new loaner 3T device at no charge pending regulatory approval and implementation of additional risk mitigation strategies worldwide, including a vacuum canister and internal sealing upgrade program and a deep disinfection service. This loaner program began in the U.S., was rolled out in Europe shortly thereafter, and is being made available progressively on a global basis, prioritizing and allocating devices to 3T device users based on pre-established criteria. We anticipate that this program will continue until we are able to address customer needs through a broader solution that includes implementation of the risk mitigation strategies described above. We are currently implementing the vacuum and sealing upgrade program in as many countries as possible until all devices are upgraded. On October 11, 2018, after review of information provided by us, the FDA concluded that we could commence the vacuum and sealing upgrade program in the U.S. Furthermore, we continue to offer a no-charge deep disinfection service (deep cleaning service) for 3T device users as we receive the required regulatory approvals. The deep disinfection service was rolled out in Europe in the second half of 2015, and on April 12, 2018, the FDA agreed to allow us to move forward with the deep cleaning service in the U.S. thereby adding to the growing list of countries around the world in which we offer this service. On December 31, 2016, we recognized a liability for our product remediation plan related to our 3T device. We concluded that it was probable that a liability had been incurred upon management’s approval of the plan and the commitments made by management to various regulatory authorities globally in November and December 2016, and furthermore, the cost associated with the plan was reasonably estimable. At September 30, 2019 , the product remediation liability was $7.4 million . Refer to “ Note 5. Product Remediation Liability ” for additional information. Litigation Product Liability The Company is currently involved in litigation involving our 3T device. The litigation includes a class action complaint in the U.S. District Court for the Middle District of Pennsylvania, federal multi-district litigation in the U.S. District Court for the Middle District of Pennsylvania, various U.S. state court cases and cases in jurisdictions outside the U.S. The class action, filed in February 2016, consists of all Pennsylvania residents who underwent open heart surgery at WellSpan York Hospital and Penn State Milton S. Hershey Medical Center between 2011 and 2015 and who currently are asymptomatic for NTM infection. Members of the class seek declaratory relief that the 3T devices are defective and unsafe for intended uses, medical monitoring, damages, and attorneys’ fees. On March 29, 2019, we announced a settlement framework that provides for a comprehensive resolution of the personal injury cases pending in the multi-district litigation in U.S. federal court, the related class action pending in federal court, as well as certain cases in state courts across the United States. The agreement, which makes no admission of liability, is subject to certain conditions, including acceptance of the settlement by individual claimants and provides for a total payment of up to $225 million to resolve the claims covered by the settlement. Per the agreed-upon terms, the first payment of $135 million was paid into a qualified settlement fund in July 2019, and the remainder will be paid in January 2020. Cases covered by the settlement will be dismissed as amounts are disbursed to individual plaintiffs from the qualified settlement fund. Cases in state courts in the U.S. and in jurisdictions outside the U.S. continue to progress. As of October 29, 2019, including the cases encompassed in the settlement framework described above that have not yet been dismissed, we are aware of approximately 100 filed and unfiled claims worldwide, with the majority of the claims in various federal or state courts throughout the United States. The complaints generally seek damages and other relief based on theories of strict liability, negligence, breach of express and implied warranties, failure to warn, design and manufacturing defect, fraudulent and negligent misrepresentation or concealment, unjust enrichment, and violations of various state consumer protection statutes. In the fourth quarter of 2018, we recognized a $294.1 million provision, which represented our best estimate of the Company’s liability for these matters. At September 30, 2019 , the provision was $153.0 million . While the amount accrued represents our best estimate, the actual liability for resolution of these matters remains uncertain and may vary from our estimate. The changes in the litigation provision liability for the nine months ended September 30, 2019 were as follows (in thousands): Litigation Provision Liability Total litigation provision liability at December 31, 2018 $ 294,061 Payments (140,823 ) FX and other (270 ) Total litigation provision liability at September 30, 2019 152,968 Less current portion of litigation provision liability at September 30, 2019 121,468 Long-term portion of litigation provision liability at September 30, 2019 $ 31,500 In July 2019, we entered into agreements with our insurance carriers to recover $33.8 million under our product liability insurance policies related to the litigation involving our 3T device. The insurance recovery was received and recognized as insurance recovery on the condensed consolidated statements of income (loss) during the three and nine months ended September 30, 2019 . Environmental Liability SNIA Litigation Our subsidiary, Sorin S.p.A. (“Sorin”) was created as a result of a spin-off (the “Sorin spin-off”) from SNIA S.p.A. (“SNIA”) in January 2004. SNIA subsequently became insolvent and the Italian Ministry of the Environment and the Protection of Land and Sea (the “Italian Ministry of the Environment”), sought compensation from SNIA in an aggregate amount of approximately $4 billion for remediation costs relating to the environmental damage at chemical sites previously operated by SNIA’s other subsidiaries. In September 2011 and July 2014, the Bankruptcy Court of Udine and the Bankruptcy Court of Milan held (in proceedings to which we are not parties) that the Italian Ministry of the Environment and other Italian government agencies (the “Public Administrations”) were not creditors of either SNIA or its subsidiaries in connection with their claims in the Italian insolvency proceedings. The Public Administrations appealed and in January 2016, the Court of Udine rejected the appeal. The Public Administrations have also appealed that decision to the Supreme Court. In addition, the Bankruptcy Court of Milan’s decision has been appealed. In January 2012, SNIA filed a civil action against Sorin in the Civil Court of Milan asserting joint liability of a parent and a spun-off company. On April 1, 2016, the Court of Milan dismissed all legal actions of SNIA and of the Public Administrations further requiring the Public Administrations to pay Sorin approximately $318,000 for legal fees. The Public Administrations appealed the 2016 Decision to the Court of Appeal of Milan. On March 5, 2019, the Court of Appeal issued a partial decision on the merits declaring Sorin/LivaNova jointly liable with SNIA for SNIA’s environmental liabilities in an amount up to the fair value of the net worth received by Sorin as a result of the Sorin spin-off. Additionally the Court issued a separate order, staying the proceeding until a panel of three experts can assess the environmental damages, the cost of clean-up, and the costs that the Public Administrations has already borne for the clean-up of the sites to allow the Court to decide on the second claim of the Public Administrations against LivaNova, (i.e., to refund the Public Administrations for the SNIA environmental liabilities). In the interim, we are appealing the decision to the Italian Supreme Court (Corte di Cassazione). We have not recognized an expense in connection with this matter because any potential loss is not currently probable or reasonably estimable. In addition, we cannot reasonably estimate a range of potential loss, if any, that may result from this matter. Opposition to Merger Proceedings On July 28, 2015, the Public Administrations filed an opposition proceeding before the Commercial Division of the Court of Milan to the merger of Sorin and Cyberonics, Inc., the predecessor companies to LivaNova. The Court authorized the merger and the Public Administrations did not appeal that decision. The proceeding then continued as a civil case, with the Public Administrations seeking damages. The Commercial Court of Milan delivered a decision in October 2016, fully rejecting the Public Administrations’ request and awarding us approximately €400,000 (approximately $436,000 as of September 30, 2019 ) in damages for frivolous litigation and legal fees. The Public Administrations appealed to the Court of Appeal of Milan. On May 15, 2018, the Court of Appeal of Milan confirmed its decision authorizing the merger but annulled the penalty for frivolous litigation and reduced the overall contribution to legal fees to €84,000 (approximately $92,000 as of September 30, 2019 ) for legal fees. The Public Administrations subsequently filed an appeal with the Supreme Court against the decision of the Court of Appeal of Milan. The proceedings before the Supreme Court are presently pending, and no decision is expected in 2019. We have not recognized an expense in connection with this matter because any potential loss is not currently probable or reasonably estimable. In addition, we cannot reasonably estimate a range of potential loss, if any, that may result from this matter. Patent Litigation On May 11, 2018, Neuro and Cardiac Technologies LLC (“NCT”), a non-practicing entity, filed a complaint in the United States District Court for the Southern District of Texas asserting that the VNS Therapy System, when used with the SenTiva Model 1000 generator, infringes the claims of U.S. Patent No. 7,076,307 owned by NCT. The complaint requests damages that include a royalty, costs, interest, and attorneys’ fees. On November 12, 2018, we petitioned the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (the “Patent Office”) for an inter partes review (“IPR”) of the validity of the ‘307 patent. The Patent Office instituted an IPR of all the challenged claims. The Court has stayed the litigation pending the outcome of the IPR proceeding. We have not recognized an expense in connection with this matter because any potential loss is not currently probable or reasonably estimable. In addition, we cannot reasonably estimate a range of potential loss, if any, that may result from this matter. Tax Litigation In a tax audit report received on October 30, 2009, the Regional Internal Revenue Office of Lombardy (the “Internal Revenue Office”) informed Sorin Group Italia S.r.l. that, among several issues, it was disallowing in part (for a total of €102.6 million (approximately $111.9 million as of September 30, 2019 ), related to tax years 2002 through 2006) a tax-deductible write down of the investment in the U.S. company, Cobe Cardiovascular Inc., which Sorin Group Italia S.r.l. recognized in 2002 and deducted in five equal installments, beginning in 2002. In December 2009, the Internal Revenue Office issued notices of assessment for 2004. In December 2010 and October 2011, the Internal Revenue Office issued notices of assessment for 2005 and 2006, respectively. We challenged all three notices of assessment (for 2004, 2005 and 2006) before the relevant Provincial Tax Courts. The preliminary challenges filed for 2004, 2005 and 2006 were denied at the first jurisdictional level. We appealed these decisions. The appeal submitted against the first-level decision for 2004 was successful. The Internal Revenue Office appealed this second-level decision to the Italian Supreme Court (Corte di Cassazione) on February 3, 2017. The Italian Supreme Court’s decision is pending. The appeals submitted against the first-level decisions for 2005 and 2006 were rejected. We appealed these adverse decisions to the Italian Supreme Court. On November 16, 2018, the Supreme Court returned the decisions for years 2005 and 2006 to the previous-level Court (Regional Tax Court) due to lack of substance of the motivation given in the 2 nd level judgments that were appealed. In November 2012, the Internal Revenue Office served a notice of assessment for 2007, and in July 2013, served a notice of assessment for 2008. In these matters the Internal Revenue Office claims an increase in taxable income due to a reduction (similar to the previous notices of assessment for 2004, 2005 and 2006) of the losses reported by Sorin Group Italia S.r.l. for the 2002, 2003 and 2004 tax periods, and subsequently utilized in 2007 and 2008. We challenged both notices of assessment. The Provincial Tax Court of Milan has stayed its decision for years 2007 and 2008 pending resolution of the litigation regarding years 2004, 2005, and 2006. The total amount of losses in dispute is €62.6 million (approximately $68.2 million as of September 30, 2019 ). We have continuously reassessed our potential exposure in these matters, taking into account the recent, and generally adverse, trend to Italian taxpayers in this type of litigation. Although we believe that our defensive arguments are strong, noting the adverse trend in some of the court decisions, we have recognized a reserve for an uncertain tax position for the full amount of the potential liability. On May 31, 2019, we filed an application to settle the litigation according to law N. 136/2018 and paid the required settlement balance of €1.9 million . As per law N. 136/2018, the Italian Revenue Agency will review the settlement and decide to accept or reject the application by July 31, 2020. Until the settlement is accepted by the Italian Revenue Agency, we will continue to reserve for the full amount of the potential liability, by recognizing a €15.4 million reserve for uncertain tax position ( $16.8 million as of September 30, 2019 ), net of the settlement payment. Other Matters Additionally, we are the subject of various pending or threatened legal actions and proceedings that arise in the ordinary course of our business. These matters are subject to many uncertainties and outcomes that are not predictable and that may not be known for extended periods of time. Since the outcome of these matters cannot be predicted with certainty, the costs associated with them could have a material adverse effect on our consolidated net income, financial position or liquidity.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 13. Stockholders’ Equity The tables below present the condensed consolidated statement of stockholders’ equity as of and for the three and nine months ended September 30, 2019 and 2018 (in thousands): Ordinary Shares Ordinary Shares - Amount Additional Paid-In Capital Treasury Stock Accumulated Other Comprehensive (Loss) Income Retained Deficit Total Stockholders' Equity June 30, 2019 49,380 $ 76,217 $ 1,717,220 $ (1,292 ) $ (13,174 ) $ (295,643 ) $ 1,483,328 Stock-based compensation plans 1 — 8,262 10 — — 8,272 Net income — — — — — 32,118 32,118 Other comprehensive loss — — — — (28,436 ) — (28,436 ) September 30, 2019 49,381 $ 76,217 $ 1,725,482 $ (1,282 ) $ (41,610 ) $ (263,525 ) $ 1,495,282 June 30, 2018 48,661 $ 75,269 $ 1,744,262 $ (109 ) $ (2,633 ) $ (33,755 ) $ 1,783,034 Stock-based compensation plans 33 42 6,624 81 — — 6,747 Net loss — — — — — (7,177 ) (7,177 ) Other comprehensive income — — — — 2,388 — 2,388 September 30, 2018 48,694 $ 75,311 $ 1,750,886 $ (28 ) $ (245 ) $ (40,932 ) $ 1,784,992 Ordinary Shares Ordinary Shares - Amount Additional Paid-In Capital Treasury Stock Accumulated Other Comprehensive (Loss) Income Retained Deficit Total Stockholders' Equity December 31, 2018 49,323 $ 76,144 $ 1,705,111 $ (1,462 ) $ (24,476 ) $ (251,579 ) $ 1,503,738 Stock-based compensation plans 58 73 20,371 180 — — 20,624 Net loss — — — — — (11,946 ) (11,946 ) Other comprehensive loss — — — — (17,134 ) — (17,134 ) September 30, 2019 49,381 $ 76,217 $ 1,725,482 $ (1,282 ) $ (41,610 ) $ (263,525 ) $ 1,495,282 December 31, 2017 48,290 $ 74,750 $ 1,735,048 $ (133 ) $ 45,313 $ (39,664 ) $ 1,815,314 Adoption of ASU No. 2016-16 — — — — — (22,430 ) (22,430 ) Share issuances 300 422 — (422 ) — — — Stock-based compensation plans 104 139 15,838 527 — — 16,504 Net income — — — — — 21,162 21,162 Other comprehensive loss — — — — (45,558 ) — (45,558 ) September 30, 2018 48,694 $ 75,311 $ 1,750,886 $ (28 ) $ (245 ) $ (40,932 ) $ 1,784,992 The table below presents the change in each component of AOCI, net of tax, and the reclassifications out of AOCI into net income for the nine months ended September 30, 2019 and 2018 (in thousands): Change in Unrealized Gain (Loss) on Derivatives Foreign Currency Translation Adjustments Gain (Loss) ( 1) Total As of December 31, 2018 $ (944 ) $ (23,532 ) $ (24,476 ) Other comprehensive income (loss) before reclassifications, before tax 933 (16,628 ) (15,695 ) Tax expense (224 ) — (224 ) Other comprehensive income (loss) before reclassifications, net of tax 709 (16,628 ) (15,919 ) Reclassification of gain from accumulated other comprehensive income (loss), before tax (1,598 ) — (1,598 ) Reclassification of tax expense 383 — 383 Reclassification of gain from accumulated other comprehensive income (loss), after tax (1,215 ) — (1,215 ) Net current-period other comprehensive loss, net of tax (506 ) (16,628 ) (17,134 ) As of September 30, 2019 $ (1,450 ) $ (40,160 ) $ (41,610 ) As of December 31, 2017 $ (919 ) $ 46,232 $ 45,313 Other comprehensive income (loss) before reclassifications, before tax 314 (36,727 ) (36,413 ) Tax expense (75 ) — (75 ) Other comprehensive income (loss) before reclassifications, net of tax 239 (36,727 ) (36,488 ) Reclassification of gain from accumulated other comprehensive income (loss), before tax (77 ) (9,011 ) (2) (9,088 ) Reclassification of tax expense 18 — 18 Reclassification of gain from accumulated other comprehensive income (loss), after tax (59 ) (9,011 ) (9,070 ) Net current-period other comprehensive income (loss), net of tax 180 (45,738 ) (45,558 ) As of September 30, 2018 $ (739 ) $ 494 $ (245 ) (1) Taxes are not provided for foreign currency translation adjustments as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned. (2) Cumulative foreign currency translation adjustments eliminated upon the sale of CRM.

Stock-Based Incentive Plans

Stock-Based Incentive Plans	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Incentive Plans	Note 14. Stock-Based Incentive Plans Stock-based incentive plans compensation expense is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Service-based restricted stock units (“RSUs”) $ 3,583 $ 3,368 $ 10,428 $ 8,158 Service-based stock appreciation rights (“SARs”) 2,896 2,491 7,804 6,514 Market performance-based restricted stock units 757 509 2,146 1,814 Operating performance-based restricted stock units 983 909 2,752 2,941 Employee stock purchase plan 312 — 997 — Total stock-based compensation expense $ 8,531 $ 7,277 $ 24,127 $ 19,427 During the nine months ended September 30, 2019 , we issued stock-based compensatory awards with terms approved by the Compensation Committee of our Board of Directors. The awards with service conditions generally vest ratably over four years , subject to forfeiture unless service conditions are met. Market performance-based awards cliff vest after three years subject to the rank of our total shareholder return for the three -year period ending December 31, 2021 relative to the total shareholder returns for a peer group of companies. Operating performance-based awards cliff vest after three years subject to the achievement of certain thresholds of cumulative adjusted free cash flow for the three year period ending December 31, 2021. Compensation expense related to awards granted during 2019 for the three and nine months ended September 30, 2019 was $3.6 million and $6.8 million , respectively. On January 1, 2019, we initiated the LivaNova Global Employee Share Purchase Plan (“ESPP”). Compensation expense related to the ESPP for the three and nine months ended September 30, 2019 was $0.3 million and $1.0 million , respectively. Stock-based compensation agreements issued during the nine months ended September 30, 2019 , representing potential shares and their weighted average grant date fair values by type follows (shares in thousands, fair value in dollars): Nine Months Ended September 30, 2019 Shares Weighted Average Grant Date Fair Value Service-based SARs 592 $ 31.22 Service-based RSUs 286 $ 93.03 Market performance-based RSUs 44 $ 100.41 Operating performance-based RSUs 44 $ 96.59

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Note 15. Income Taxes Our effective income tax rate from continuing operations for the three and nine months ended September 30, 2019 was (49.6)% and 65.9% , respectively, compared with 29.8% and 0.6% the three and nine months ended September 30, 2018 , respectively. Our effective income tax rate fluctuates based on, among other factors, changes in pretax income in countries with varying statutory tax rates, changes in valuation allowances, changes in tax credits and incentives, and changes in unrecognized tax benefits associated with uncertain tax positions. Compared with the three and nine months ended September 30, 2018 , the change in the effective tax rate for the three and nine months ended September 30, 2019 was primarily attributable to a release of uncertain tax positions and a U.S. federal tax benefit from a return to provision adjustment, partly offset by the establishment of a valuation allowance for a portion of the U.S. state net operating losses and attributes. We operate in multiple jurisdictions throughout the world, and our tax returns are periodically audited or subjected to review by tax authorities. As a result, there is an uncertainty in income taxes recognized in our financial statements. Tax benefits totaling $16.6 million and $22.9 million were unrecognized as of September 30, 2019 and December 31, 2018 , respectively. It is reasonably possible that, within the next twelve months, due to the settlement of uncertain tax positions with various tax authorities and the expiration of statutes of limitations, unrecognized tax benefits could decrease by up to approximately $1.3 million . We monitor income tax developments in countries where we conduct business. In 2017, the U.S. enacted the “Tax Cuts and Jobs Act” (the “Tax Act”). To determine the full effects of the Tax Act, we are awaiting the finalization of several proposed U.S. Treasury regulations that were issued during 2018, as well as additional regulations to be proposed and finalized pursuant to the U.S. Treasury’s expanded regulatory authority under the Tax Act. It is also possible that technical correction legislation concerning the Tax Act could retroactively affect tax liabilities for 2018. In addition, state legislative changes addressing conformity to the Tax Act are still pending.

Net Income Per Share

Net Income Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Net Income Per Share	Note 16. Net Income Per Share Reconciliation of the shares used in the basic and diluted earnings per share computations for the three and nine months ended September 30, 2019 and 2018 are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Basic weighted average shares outstanding 48,395 48,637 48,329 48,484 Add effects of share-based compensation instruments (1) 425 — — 943 Diluted weighted average shares outstanding 48,820 48,637 48,329 49,427 (1) Excluded from the computation of diluted earnings per share were stock options, SARs and restricted share units totaling 1.4 million and 2.8 million for the three months ended September 30, 2019 and 2018 , respectively, and 3.1 million and 0.5 million for the nine months ended September 30, 2019 and 2018 , respectively, because to include them would have been anti-dilutive under the treasury stock method.

Geographic and Segment Informat

Geographic and Segment Information	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Geographic and Segment Information	Note 17. Geographic and Segment Information We identify operating segments based on the way we manage, evaluate and internally report our business activities for purposes of allocating resources, developing and executing our strategy, and assessing performance. We have two reportable segments: Cardiovascular and Neuromodulation. The Cardiovascular segment generates its revenue from the development, production and sale of cardiopulmonary products, heart valves and advanced circulatory support. Cardiopulmonary products include oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae and other related accessories. Heart valves include mechanical heart valves, tissue heart valves and related repair products. Advanced circulatory support includes temporary life support product kits that can include a combination of pumps, oxygenators, and cannulae. On June 12, 2019, we acquired the minimally invasive cardiac surgery instruments business from Miami Instruments, which are integrated into our Cardiovascular business franchise as part of our Heart Valves portfolio. Our Neuromodulation segment generates its revenue from the design, development and marketing of neuromodulation therapy systems for the treatment of drug-resistant epilepsy and treatment-resistant depression (“TRD”). Neuromodulation products include the VNS Therapy System, which consists of an implantable pulse generator, a lead that connects the generator to the vagus nerve, and other accessories. Our Neuromodulation segment also includes an implantable device for the treatment of obstructive sleep apnea that stimulates multiple tongue muscles via the hypoglossal nerve, which opens the airway while a patient is sleeping. “Other” includes corporate shared service expenses for finance, legal, human resources and information technology and corporate business development and New Ventures. Net sales of our reportable segments include revenues from the sale of products they each develop and manufacture or distribute. We define segment income as operating income before merger and integration, restructuring and amortization of intangibles. We operate under three geographic regions: U.S., Europe, and Rest of world. The table below presents net sales by operating segment and geographic region (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Cardiopulmonary United States $ 39,054 $ 40,396 $ 119,580 $ 120,980 Europe 30,052 32,186 99,933 104,972 Rest of world 50,908 55,358 152,650 163,757 120,014 127,940 372,163 389,709 Heart Valves United States 4,626 6,145 13,660 18,828 Europe 9,572 9,421 30,757 33,400 Rest of world 14,679 16,980 43,484 45,162 28,877 32,546 87,901 97,390 Advanced Circulatory Support United States 6,313 5,947 22,290 11,415 Europe 186 38 497 391 Rest of world 36 90 310 284 6,535 6,075 23,097 12,090 Cardiovascular United States 49,993 52,488 155,530 151,223 Europe 39,810 41,645 131,187 138,763 Rest of world 65,623 72,428 196,444 209,203 155,426 166,561 483,161 499,189 Neuromodulation United States 88,433 87,194 245,870 254,581 Europe 10,425 9,497 34,080 31,731 Rest of world 13,685 8,252 31,511 23,128 112,543 104,943 311,461 309,440 Other 641 578 1,958 1,349 Totals United States 138,426 139,682 401,400 405,804 Europe (1) 50,235 51,142 165,267 170,494 Rest of world 79,949 81,258 229,913 233,680 Total (2) $ 268,610 $ 272,082 $ 796,580 $ 809,978 (1) Europe sales include those countries in which we have a direct sales presence, whereas European countries in which we sell through distributors are included in Rest of world. (2) No single customer represented over 10% of our consolidated net sales. No country’s net sales exceeded 10% of our consolidated sales except for the U.S. The table below presents a reconciliation of segment income from continuing operations to consolidated income from continuing operations before tax (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Operating Income (Loss) from Continuing Operations 2019 2018 2019 2018 Cardiovascular (1) $ 36,180 $ 9,783 $ 47,289 $ 36,378 Neuromodulation (2) 30,010 36,432 52,260 132,377 Other (21,869 ) (29,420 ) (75,845 ) (89,479 ) Total reportable segment income from continuing operations 44,321 16,795 23,704 79,276 Merger and integration expenses 6,716 12,659 14,345 20,028 Restructuring expenses 698 436 4,563 2,793 Amortization of intangibles 11,146 9,457 29,690 28,075 Operating income (loss) from continuing operations 25,761 (5,757 ) (24,894 ) 28,380 Interest income 151 184 624 863 Interest expense (4,774 ) (2,633 ) (10,490 ) (7,750 ) Gain on acquisition — — — 11,484 Foreign exchange and other gains (losses) 327 (727 ) (795 ) (1,070 ) Income (loss) from continuing operations before tax $ 21,465 $ (8,933 ) $ (35,555 ) $ 31,907 (1) Results for the three and nine months ended September 30, 2019 include an insurance recovery of $33.8 million . Refer to “ Note 12. Commitments and Contingencies ” for additional information. (2) Results for the nine months ended September 30, 2019 include the impairment of intangible assets of $50.3 million . Assets by reportable segment are as follows (in thousands): Assets September 30, 2019 December 31, 2018 Cardiovascular $ 1,511,639 $ 1,532,825 Neuromodulation 696,666 731,840 Other 301,636 285,036 Total assets $ 2,509,941 $ 2,549,701 Capital expenditures by segment are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Capital expenditures 2019 2018 2019 2018 Cardiovascular $ 5,178 $ 8,032 $ 13,564 $ 15,757 Neuromodulation 136 512 666 1,359 Other 691 4,359 2,571 7,058 Discontinued operations — — — 925 Total $ 6,005 $ 12,903 $ 16,801 $ 25,099 The changes in the carrying amount of goodwill by reportable segment for the nine months ended September 30, 2019 were as follows (in thousands): Neuromodulation Cardiovascular Other Total December 31, 2018 $ 398,539 $ 515,859 $ 42,417 $ 956,815 Goodwill as a result of acquisitions — 1,550 — 1,550 Measurement period adjustments — (3,326 ) — (3,326 ) Foreign currency adjustments 215 (9,710 ) — (9,495 ) September 30, 2019 $ 398,754 $ 504,373 $ 42,417 $ 945,544 Property, plant and equipment, net by geography are as follows (in thousands): PP&E September 30, 2019 December 31, 2018 United States $ 63,473 $ 68,862 Europe 106,066 112,376 Rest of world 9,968 10,162 Total $ 179,507 $ 191,400

Supplemental Financial Informat

Supplemental Financial Information	9 Months Ended
	Sep. 30, 2019
Balance Sheet Related Disclosures [Abstract]
Supplemental Financial Information	Note 18. Supplemental Financial Information Inventories consisted of the following (in thousands): September 30, 2019 December 31, 2018 Raw materials $ 45,239 $ 40,387 Work-in-process 18,245 15,999 Finished goods 104,272 97,149 $ 167,756 $ 153,535 Inventories are reported net of the provision for obsolescence. This provision, which reflects normal obsolescence and includes components that are phased out or expired, totaled $10.9 million and $11.6 million at September 30, 2019 and December 31, 2018 , respectively. Accrued liabilities and other consisted of the following (in thousands): September 30, 2019 December 31, 2018 Contingent consideration (1) $ 24,802 $ 18,530 CRM purchase price adjustment payable to MicroPort Scientific Corporation 14,891 14,891 Legal and administrative costs 13,200 9,189 Operating lease liabilities (2) 10,565 — Product remediation (3) 7,444 13,945 Contract liabilities 5,628 3,304 Research and development costs 5,109 1,841 Provisions for agents, returns and other 4,038 4,934 Restructuring related liabilities (4) 2,621 9,393 Derivative contract liabilities (5) 3,455 5,063 Other amounts payable to MicroPort Scientific Corporation 852 9,319 Other accrued expenses 35,851 33,876 $ 128,456 $ 124,285 (1) Refer to “ Note 8. Fair Value Measurements ” (2) Refer to “ Note 11. Leases ” (3) Refer to “ Note 5. Product Remediation Liability ” (4) Refer to “ Note 4. Restructuring ” (5) Refer to “ Note 10. Derivatives and Risk Management ” As of September 30, 2019 and December 31, 2018 , contract liabilities of $7.1 million and $4.8 million , respectively, are included within accrued liabilities and other long-term liabilities on the condensed consolidated balance sheets.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	Note 19. New Accounting Pronouncements Adoption of New Accounting Pronouncements The following table provides a description of our adoption of new Accounting Standards Updates (“ASUs”) issued by the FASB and the impact of the adoption on our condensed financial statements: Issue Date & Standard Description Date of Adoption Effect on Financial Statements or Other Significant Matters February 2016 ASU No. 2016-02, Leases (Topic 842) and subsequent amendments The standard requires lessees to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use (“ROU”) assets and to provide enhanced disclosures. Furthermore, from a lessor perspective, certain of our agreements that allow the customer to use, rather than purchase, our medical devices met the criteria of being a lease in accordance with the new standard. January 1, 2019 Adoption of the new standard resulted in the recognition of ROU assets and lease liabilities of approximately $60 million as of January 1, 2019. Refer to “Note 11. Leases.” June 2018 ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting This update simplifies the accounting for non-employee share-based payment transactions. January 1, 2019 There was no material impact to our condensed consolidated financial statements as a result of adopting this ASU. Future Adoption of New Accounting Pronouncements The following table provides a description of future adoptions of new accounting standards that may have an impact on our financial statements when adopted: Issue Date & Standard Description Projected Date of Adoption Effect on Financial Statements or Other Significant Matters June 2016 ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326) The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The modified-retrospective approach is generally applicable through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Early adoption is permitted. January 1, 2020 We are currently evaluating the effect this standard will have on our condensed consolidated financial statements and related disclosures. January 2017 ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment This update removes step 2 of the goodwill impairment test that compares the implied fair value of goodwill with its carrying amount. Instead, an impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge will be recorded by the amount a reporting unit’s carrying amount exceeds its fair value. Early adoption is permitted. January 1, 2020 We are currently evaluating the effect this standard will have on our condensed consolidated financial statements and related disclosures. August 2018 ASU No. 2018-13, Fair Value Measurement (Topic 820): Changes to the Disclosure Requirements for Fair Value Measurement This update removes, modifies and adds certain disclosure requirements related to fair value measurements. Early adoption is permitted. January 1, 2020 We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statement disclosures. August 2018 ASU No. 2018-14, Compensation—Retirement Benefits—Defined Benefit Plans—General (Subtopic 715-20): Changes to the Disclosure Requirements for Defined Benefit Plans This update adds and removes certain disclosure requirements related to defined benefit plans. This ASU is to be implemented on a retrospective basis for all periods presented with early adoption permitted. January 1, 2021 We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statement disclosures. August 2018 ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract This update clarifies and aligns the accounting for implementation costs for hosting arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is to be applied either retrospectively or prospectively with early adoption permitted. January 1, 2020 We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statements.

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Financial Statements (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements of LivaNova as of, and for the three and nine months ended September 30, 2019 and 2018 , have been prepared in accordance with U.S. GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying condensed consolidated balance sheet of LivaNova at December 31, 2018 has been derived from audited financial statements contained in our 2018 Form 10-K, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair statement of the operating results of LivaNova and its subsidiaries, for the three and nine months ended September 30, 2019 , and are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 . The financial information presented herein should be read in conjunction with the audited consolidated financial statements and notes thereto accompanying our 2018 Form 10-K.
New Accounting Pronouncements	On January 1, 2019, we adopted ASC Update (“ASU”) No 2016-02, Leases , including subsequent related accounting updates (collectively referred to as “Topic 842”), which supersedes the previous accounting model for leases. We adopted the standard using the modified retrospective approach with an effective date as of January 1, 2019. Prior year financial statements were not recast under the new standard. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward our historical assessment of whether contracts are or contain leases and lease classification. We also elected the practical expedient to account for lease and non-lease components together as a single combined lease component, which is applicable to all asset classes. We did not, however, elect the practical expedient related to using hindsight in determining the lease term as this was not relevant following our election of the modified retrospective approach. In addition, we elect certain practical expedients on an ongoing basis, including the practical expedient for short-term leases pursuant to which a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize a lease liability and operating lease asset for leases with a term of 12 months or less and that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. We have applied this accounting policy to all asset classes in our portfolio and will recognize the lease payments for such short-term leases within profit and loss on a straight-line basis over the lease term. Furthermore, from a lessor perspective, certain of our agreements that allow the customer to use, rather than purchase, our medical devices will meet the criteria of being a lease in accordance with the new standard. While the amount of revenue and expenses recognized over the contract term will not be impacted, the timing of revenue and expense recognition will be impacted depending upon lease classification. We enacted appropriate changes to our business processes, systems and internal controls to support identification, recognition and disclosure of leases under the new standard. We determine if an arrangement is or contains a lease at inception. Operating lease assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the latter of our lease standard effective date for adoption or the lease commencement date. Variable lease payments, such as common area rent maintenance charges and rent escalations not known upon lease commencement, are not included in determination of the minimum lease payments and will be expensed in the period in which the obligation for those payments is incurred. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement in determining the present value of future payments. The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. We used the incremental borrowing rate available nearest to our adoption date for leases that commenced prior to that date. The operating lease asset also includes any lease payments made in advance and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For additional information refer to “ Note 11. Leases Adoption of New Accounting Pronouncements The following table provides a description of our adoption of new Accounting Standards Updates (“ASUs”) issued by the FASB and the impact of the adoption on our condensed financial statements: Issue Date & Standard Description Date of Adoption Effect on Financial Statements or Other Significant Matters February 2016 ASU No. 2016-02, Leases (Topic 842) and subsequent amendments The standard requires lessees to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use (“ROU”) assets and to provide enhanced disclosures. Furthermore, from a lessor perspective, certain of our agreements that allow the customer to use, rather than purchase, our medical devices met the criteria of being a lease in accordance with the new standard. January 1, 2019 Adoption of the new standard resulted in the recognition of ROU assets and lease liabilities of approximately $60 million as of January 1, 2019. Refer to “Note 11. Leases.” June 2018 ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting This update simplifies the accounting for non-employee share-based payment transactions. January 1, 2019 There was no material impact to our condensed consolidated financial statements as a result of adopting this ASU. Future Adoption of New Accounting Pronouncements The following table provides a description of future adoptions of new accounting standards that may have an impact on our financial statements when adopted: Issue Date & Standard Description Projected Date of Adoption Effect on Financial Statements or Other Significant Matters June 2016 ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326) The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The modified-retrospective approach is generally applicable through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Early adoption is permitted. January 1, 2020 We are currently evaluating the effect this standard will have on our condensed consolidated financial statements and related disclosures. January 2017 ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment This update removes step 2 of the goodwill impairment test that compares the implied fair value of goodwill with its carrying amount. Instead, an impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge will be recorded by the amount a reporting unit’s carrying amount exceeds its fair value. Early adoption is permitted. January 1, 2020 We are currently evaluating the effect this standard will have on our condensed consolidated financial statements and related disclosures. August 2018 ASU No. 2018-13, Fair Value Measurement (Topic 820): Changes to the Disclosure Requirements for Fair Value Measurement This update removes, modifies and adds certain disclosure requirements related to fair value measurements. Early adoption is permitted. January 1, 2020 We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statement disclosures. August 2018 ASU No. 2018-14, Compensation—Retirement Benefits—Defined Benefit Plans—General (Subtopic 715-20): Changes to the Disclosure Requirements for Defined Benefit Plans This update adds and removes certain disclosure requirements related to defined benefit plans. This ASU is to be implemented on a retrospective basis for all periods presented with early adoption permitted. January 1, 2021 We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statement disclosures. August 2018 ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract This update clarifies and aligns the accounting for implementation costs for hosting arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is to be applied either retrospectively or prospectively with early adoption permitted. January 1, 2020 We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statements.
Derivatives	If the derivative qualifies for hedge accounting, changes in the fair value of the derivative will be recorded in accumulated other comprehensive income (“AOCI”) until the hedged item is recognized in earnings upon settlement/termination. FX derivative gains and losses in AOCI are reclassified to our condensed consolidated statements of income (loss) as shown in the tables below and interest rate swap gains and losses in AOCI are reclassified to interest expense on our condensed consolidated statements of income (loss). We evaluate hedge effectiveness at inception and on an ongoing basis. If a derivative is no longer expected to be highly effective, hedge accounting is discontinued and the gains or losses are reclassified into earnings. Cash flows from derivative contracts are reported as operating activities on our condensed consolidated statements of cash flows.

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]
Components of Discontinued Operations	The following table represents the financial results of CRM presented as net (loss) income from discontinued operations in the condensed consolidated statements of income (loss) (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net sales $ — $ — $ — $ 77,366 Costs and expenses: Cost of sales — — (43 ) 27,306 Selling, general and administrative expenses — 543 26 43,441 Research and development — — (161 ) 16,577 Restructuring expenses — — — 651 Revaluation gain on assets and liabilities held for sale — — — (1,213 ) Loss on sale of CRM — — — 214 Operating (loss) income from discontinued operations — (543 ) 178 (9,610 ) Foreign exchange and other gains — — — 102 (Loss) income from discontinued operations, before tax — (543 ) 178 (9,508 ) Income tax expense (benefit) — 361 — (804 ) Losses from equity method investments — — — (1,211 ) Net (loss) income from discontinued operations $ — $ (904 ) $ 178 $ (9,915 )

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The following table presents the accruals, inventory obsolescence and other reserves, recorded in connection with our reorganization plans (in thousands): Employee Severance and Other Termination Costs Other Total Balance at December 31, 2018 $ 10,195 $ 3,069 $ 13,264 Charges 4,488 75 4,563 Cash payments and other (13,147 ) (2,059 ) (15,206 ) Balance at September 30, 2019 (1) $ 1,536 $ 1,085 $ 2,621 (1) Cumulatively, we have recognized a total of $103.8 million in restructuring expense inclusive of discontinued operations under the Prior Plans and the 2018 Plan.
Schedule of Restructuring Expense by Reportable Segment	The following table presents restructuring expense by reportable segment (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Cardiovascular $ 783 $ 354 $ 1,521 $ 2,093 Neuromodulation (171 ) 17 314 34 Other 86 65 2,728 666 Total $ 698 $ 436 $ 4,563 $ 2,793

Product Remediation Liability (

Product Remediation Liability (Tables)	9 Months Ended
	Sep. 30, 2019
Product Remediation [Abstract]
Product Liability Contingencies	Changes in the carrying amount of the product remediation liability are as follows (in thousands): Balance at December 31, 2018 $ 14,745 Adjustments 2,567 Remediation activity (9,341 ) Effect of changes in foreign currency exchange rates (527 ) Balance at September 30, 2019 (1) $ 7,444 (1) At September 30, 2019 , the product remediation liability balance is included within accrued liabilities and other on the condensed consolidated balance sheet.

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2019
Investments [Abstract]
Schedule of Long-term Investments	These equity investments are included in investments on the condensed consolidated balance sheets (in thousands): Equity Investments Without Readily Determinable Fair Values September 30, 2019 December 31, 2018 Respicardia Inc. (1) $ 17,706 $ 17,706 Ceribell, Inc. 3,000 3,000 Rainbow Medical Ltd. 1,067 1,119 MD Start II 1,090 1,144 Highlife S.A.S. 1,034 1,084 Other 770 770 24,667 24,823 Equity method investments (2) 275 — $ 24,942 $ 24,823 (1) Respicardia Inc. (“Respicardia”) is a privately funded U.S. company developing an implantable device designed to restore a more natural breathing pattern during sleep in patients with central sleep apnea by transvenously stimulating the phrenic nerve. We have a loan outstanding to Respicardia, with a carrying amount of $0.6 million as of September 30, 2019 and December 31, 2018 , which is included in prepaid expenses and other current assets in the condensed consolidated balance sheet. (2) During the second quarter of 2019, we invested in equity securities that we account for under the equity method of accounting due to our deemed ability to exercise significant influence. We initially invested $0.3 million and are required to fund up to a total of approximately €5.0 million (approximately $5.5 million as of September 30, 2019 ) based on cash calls.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements on a Recurring Basis	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands): Fair Value as of September 30, 2019 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - freestanding instruments (FX) $ 1,213 $ — $ 1,213 $ — $ 1,213 $ — $ 1,213 $ — Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 1,458 $ — $ 1,458 $ — Derivative liabilities - designated as cash flow hedges (interest rate swaps) 519 — 519 — Derivative liabilities - freestanding instruments (FX) 1,869 — 1,869 — Contingent consideration (1) 165,274 — — 165,274 $ 169,120 $ — $ 3,846 $ 165,274 Fair Value as of December 31, 2018 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - freestanding instruments (FX) $ 236 $ — $ 236 $ — $ 236 $ — $ 236 $ — Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 1,354 $ — $ 1,354 $ — Derivative liabilities - designated as cash flow hedges (interest rate swaps) 865 — 865 — Derivative liabilities - freestanding instruments (FX) 3,173 — 3,173 — Contingent consideration (1) 179,911 — — 179,911 $ 185,303 $ — $ 5,392 $ 179,911 (1) The contingent consideration liability represents contingent payments primarily related to five completed acquisitions, including: Inversiones Drilltex SAS (“Drilltex”), Caisson, ImThera, TandemLife and Miami Instruments. See the table below for additional information.
Reconciliation of Beginning and Ending Balances of Contingent Consideration	The following table provides a reconciliation of the beginning and ending balance of the contingent consideration liability (in thousands): Total contingent consideration liability at December 31, 2018 $ 179,911 Additions (1) 7,184 Payments (2) (19,234 ) Changes in fair value (3) (4) (2,425 ) Effect of changes in foreign currency exchange rates (162 ) Total contingent consideration liability at September 30, 2019 165,274 Less current portion of contingent consideration liability at September 30, 2019 24,802 Long-term portion of contingent consideration liability at September 30, 2019 $ 140,472 (1) See “ Note 2. Business Combinations ” for additional discussion. (2) In July 2019, we achieved a regulatory milestone upon receiving FDA approval of the LifeSPARC system, triggering the payment of $19.0 million during the third quarter of 2019 to settle the related contingent consideration liability in connection with our TandemLife acquisition. The probability of additional payments and projected years of payment for the remaining regulatory milestones, as outlined in our TandemLife acquisition, remain unchanged. (3) The change in fair value includes a decrease of $17.8 million that was recognized during the second quarter of 2019 primarily due to the delay in timing of anticipated regulatory approval and commercialization for ImThera. While the probability of payment remains unchanged from the time of acquisition, the projected years of payment for the regulatory milestone-based payment and the sales-based earnout have been updated to occur between 2023-2024 and 2024-2028, respectively. See “ Note 6. Intangible Assets ” for additional discussion. This decrease was largely offset by impacts from the change in interest rates and the passage of time subsequent to December 31, 2018. (4) During the nine months ended September 30, 2019 , the change in fair value resulted in a decrease of $0.9 million and $1.5 million recorded to cost of sales - exclusive of amortization and research and development, respectively.

Financing Arrangements (Tables)

Financing Arrangements (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The outstanding principal amount of long-term debt (in thousands, except interest rates): September 30, 2019 December 31, 2018 Maturity Interest Rate 2019 Debt Facility (1) $ 182,434 $ — March 2022 1.40% - 3.72% 2017 European Investment Bank (2) 103,570 103,570 June 2026 3.47% - 3.53% 2014 European Investment Bank (3) 36,317 47,606 June 2021 0.98% Mediocredito Italiano 6,674 7,623 December 2023 0.50% - 2.86% Bank of America Merrill Lynch Banco Múltiplo S.A. 4,898 — July 2021 8.47% Bank of America, U.S. 1,999 — January 2021 4.51% Banca del Mezzogiorno 1,304 2,718 December 2019 0.50% - 2.91% Other 1,375 1,324 Total long-term facilities 338,571 162,841 Less current portion of long-term debt 65,684 23,303 Total long-term debt $ 272,887 $ 139,538 (1) The facility agreement with Bank of America Merrill Lynch International DAC, Barclays Bank PLC, BNP Paribas (London Branch) and Intesa Sanpaolo S.P.A. provides a multicurrency term loan facility in an aggregate amount of $350 million and terminates on March 26, 2022 (the “2019 Debt Facility”). Principal repayments of 20% of the outstanding borrowings under the 2019 Debt Facility are due in September 2020, March 2021 and September 2021, with the remainder of the outstanding borrowings due in March 2022. (2) The 2017 European Investment Bank (“2017 EIB”) loan was obtained to support certain product development projects. The interest rate for the 2017 EIB loan is reset by the lender each principal payment date based on LIBOR. Interest payments are paid quarterly and principal payments are paid semi-annually. (3) The 2014 European Investment Bank (“2014 EIB”) loan was obtained in July 2014 to support certain product development projects. The interest rate for the 2014 EIB loan is reset by the lender each quarter based on the Euribor. Interest payments are paid quarterly and principal payments are paid semi-annually.

Derivatives and Risk Manageme_2

Derivatives and Risk Management (Tables)	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Derivative Contracts Designated Cash Flow Hedges	Notional amounts of open derivative contracts designated as cash flow hedges (in thousands): Description of Derivative Contract September 30, 2019 December 31, 2018 FX derivative contracts to be exchanged for British Pounds $ 8,185 $ 9,629 FX derivative contracts to be exchanged for Japanese Yen 26,462 23,985 FX derivative contracts to be exchanged for Canadian Dollars 1,532 7,637 FX derivative contracts to be exchanged for Euros 29,563 29,768 Interest rate swap contracts 29,072 38,115 $ 94,814 $ 109,134
Unrealized Gain (Loss) in AOCI	After-tax net loss associated with derivatives designated as cash flow hedges recorded in the ending balance of AOCI and the amount expected to be reclassified to earnings in the next twelve months (in thousands): Description of Derivative Contract After-Tax Net Loss in AOCI as of September 30, 2019 Amount Expected to be Reclassified to Earnings in Next 12 Months FX derivative contracts $ (1,313 ) $ (1,313 ) Interest rate swap contracts (137 ) (78 ) $ (1,450 ) $ (1,391 )
Schedule of Cash Flow Hedges Included in AOCI	Pre-tax gains (losses) for derivative contracts designated as cash flow hedges recognized in other comprehensive income (loss) (“OCI”) and the amount reclassified to earnings from AOCI (in thousands): Three Months Ended September 30, 2019 2018 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Losses Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings Gains Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other (losses) gains $ (689 ) $ 963 $ 125 $ 2,511 FX derivative contracts SG&A — (742 ) — (3,007 ) Interest rate swap contracts Interest expense — (40 ) — (72 ) $ (689 ) $ 181 $ 125 $ (568 ) Nine Months Ended September 30, 2019 2018 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Gains Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings Gains Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other gains (losses) $ 933 $ 3,094 $ 314 $ 1,999 FX derivative contracts SG&A — (1,470 ) — (1,833 ) Interest rate swap contracts Interest expense — (26 ) — (89 ) $ 933 $ 1,598 $ 314 $ 77
Schedule of Fair Value of Derivative Instruments in Statement of Financial Position	The following tables present the fair value and the location of derivative contracts reported in the condensed consolidated balance sheets (in thousands): September 30, 2019 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) Interest rate swap contracts Accrued liabilities $ 385 Interest rate swap contracts Other long-term liabilities 134 FX derivative contracts Accrued liabilities 1,201 FX derivative contracts Prepaid expenses and other current assets 257 Total derivatives designated as hedging instruments 1,977 Derivatives Not Designated as Hedging Instruments FX derivative contracts Prepaid expenses and other current assets $ 1,213 Accrued liabilities 1,869 Total derivatives not designated as hedging instruments 1,213 1,869 Total derivatives $ 1,213 $ 3,846 December 31, 2018 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) Interest rate swap contracts Accrued liabilities $ 536 Interest rate swap contracts Other long-term liabilities 329 FX derivative contracts Accrued liabilities 1,354 Total derivatives designated as hedging instruments 2,219 Derivatives Not Designated as Hedging Instruments FX derivative contracts Prepaid expenses and other current assets $ 236 Accrued liabilities 3,173 Total derivatives not designated as hedging instruments 236 3,173 Total derivatives $ 236 $ 5,392 (1) For the classification of inputs used to evaluate the fair value of our derivatives, refer to “ Note 8. Fair Value Measurements .”

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Assets and Liabilities, Lessee	The components of operating lease assets, liabilities and costs are as follows (in thousands): Operating Lease Assets and Liabilities September 30, 2019 Assets Operating lease right-of-use assets $ 54,283 Liabilities Accrued liabilities and other $ 10,565 Long-term operating lease liabilities 44,724 Total lease liabilities $ 55,289
Lease, Cost	Operating Lease Cost Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Operating lease cost $ 3,391 $ 10,600 Variable lease cost 225 651 Short-term lease cost 258 538 Total lease cost $ 3,874 $ 11,789 Lease Term and Discount Rate September 30, 2019 Weighted Average Remaining Lease Term (in years) 7.3 Weighted Average Discount Rate 2.3 %
Lessee, Operating Lease, Liability, Maturity	Contractual maturities of our lease liabilities as of September 30, 2019 , are as follows (in thousands): Remaining 2019 $ 2,728 2020 11,309 2021 9,411 2022 8,263 2023 6,913 Thereafter 21,866 Total lease payments 60,490 Less: Amount representing interest 5,201 Present value of lease liabilities $ 55,289
Schedule of Cash Flow, Supplemental Disclosures	Other Information (in thousands) Nine Months Ended September 30, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 10,111 Operating lease assets obtained in exchange for lease liabilities $ 5,403
Schedule of Future Minimum Rental Payments for Operating Leases	As required and as previously disclosed in our 2018 Form 10-K, the following table summarizes our future minimum operating lease payments as of December 31, 2018 (in thousands): Less than one year $ 11,986 One to three years 21,031 Three to five years 14,998 Thereafter 20,943 Total $ 68,958

Commitments and Contingencies L

Commitments and Contingencies Litigation (Tables)	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Litigation Provision Liabilities	The changes in the litigation provision liability for the nine months ended September 30, 2019 were as follows (in thousands): Litigation Provision Liability Total litigation provision liability at December 31, 2018 $ 294,061 Payments (140,823 ) FX and other (270 ) Total litigation provision liability at September 30, 2019 152,968 Less current portion of litigation provision liability at September 30, 2019 121,468 Long-term portion of litigation provision liability at September 30, 2019 $ 31,500

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity	The tables below present the condensed consolidated statement of stockholders’ equity as of and for the three and nine months ended September 30, 2019 and 2018 (in thousands): Ordinary Shares Ordinary Shares - Amount Additional Paid-In Capital Treasury Stock Accumulated Other Comprehensive (Loss) Income Retained Deficit Total Stockholders' Equity June 30, 2019 49,380 $ 76,217 $ 1,717,220 $ (1,292 ) $ (13,174 ) $ (295,643 ) $ 1,483,328 Stock-based compensation plans 1 — 8,262 10 — — 8,272 Net income — — — — — 32,118 32,118 Other comprehensive loss — — — — (28,436 ) — (28,436 ) September 30, 2019 49,381 $ 76,217 $ 1,725,482 $ (1,282 ) $ (41,610 ) $ (263,525 ) $ 1,495,282 June 30, 2018 48,661 $ 75,269 $ 1,744,262 $ (109 ) $ (2,633 ) $ (33,755 ) $ 1,783,034 Stock-based compensation plans 33 42 6,624 81 — — 6,747 Net loss — — — — — (7,177 ) (7,177 ) Other comprehensive income — — — — 2,388 — 2,388 September 30, 2018 48,694 $ 75,311 $ 1,750,886 $ (28 ) $ (245 ) $ (40,932 ) $ 1,784,992 Ordinary Shares Ordinary Shares - Amount Additional Paid-In Capital Treasury Stock Accumulated Other Comprehensive (Loss) Income Retained Deficit Total Stockholders' Equity December 31, 2018 49,323 $ 76,144 $ 1,705,111 $ (1,462 ) $ (24,476 ) $ (251,579 ) $ 1,503,738 Stock-based compensation plans 58 73 20,371 180 — — 20,624 Net loss — — — — — (11,946 ) (11,946 ) Other comprehensive loss — — — — (17,134 ) — (17,134 ) September 30, 2019 49,381 $ 76,217 $ 1,725,482 $ (1,282 ) $ (41,610 ) $ (263,525 ) $ 1,495,282 December 31, 2017 48,290 $ 74,750 $ 1,735,048 $ (133 ) $ 45,313 $ (39,664 ) $ 1,815,314 Adoption of ASU No. 2016-16 — — — — — (22,430 ) (22,430 ) Share issuances 300 422 — (422 ) — — — Stock-based compensation plans 104 139 15,838 527 — — 16,504 Net income — — — — — 21,162 21,162 Other comprehensive loss — — — — (45,558 ) — (45,558 ) September 30, 2018 48,694 $ 75,311 $ 1,750,886 $ (28 ) $ (245 ) $ (40,932 ) $ 1,784,992
Schedule of Accumulated Other Comprehensive Income (Loss)	The table below presents the change in each component of AOCI, net of tax, and the reclassifications out of AOCI into net income for the nine months ended September 30, 2019 and 2018 (in thousands): Change in Unrealized Gain (Loss) on Derivatives Foreign Currency Translation Adjustments Gain (Loss) ( 1) Total As of December 31, 2018 $ (944 ) $ (23,532 ) $ (24,476 ) Other comprehensive income (loss) before reclassifications, before tax 933 (16,628 ) (15,695 ) Tax expense (224 ) — (224 ) Other comprehensive income (loss) before reclassifications, net of tax 709 (16,628 ) (15,919 ) Reclassification of gain from accumulated other comprehensive income (loss), before tax (1,598 ) — (1,598 ) Reclassification of tax expense 383 — 383 Reclassification of gain from accumulated other comprehensive income (loss), after tax (1,215 ) — (1,215 ) Net current-period other comprehensive loss, net of tax (506 ) (16,628 ) (17,134 ) As of September 30, 2019 $ (1,450 ) $ (40,160 ) $ (41,610 ) As of December 31, 2017 $ (919 ) $ 46,232 $ 45,313 Other comprehensive income (loss) before reclassifications, before tax 314 (36,727 ) (36,413 ) Tax expense (75 ) — (75 ) Other comprehensive income (loss) before reclassifications, net of tax 239 (36,727 ) (36,488 ) Reclassification of gain from accumulated other comprehensive income (loss), before tax (77 ) (9,011 ) (2) (9,088 ) Reclassification of tax expense 18 — 18 Reclassification of gain from accumulated other comprehensive income (loss), after tax (59 ) (9,011 ) (9,070 ) Net current-period other comprehensive income (loss), net of tax 180 (45,738 ) (45,558 ) As of September 30, 2018 $ (739 ) $ 494 $ (245 ) (1) Taxes are not provided for foreign currency translation adjustments as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned. (2) Cumulative foreign currency translation adjustments eliminated upon the sale of CRM.

Stock-Based Incentive Plan (Tab

Stock-Based Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Share-based Compensation, Stock Options, Activity	Stock-based compensation agreements issued during the nine months ended September 30, 2019 , representing potential shares and their weighted average grant date fair values by type follows (shares in thousands, fair value in dollars): Nine Months Ended September 30, 2019 Shares Weighted Average Grant Date Fair Value Service-based SARs 592 $ 31.22 Service-based RSUs 286 $ 93.03 Market performance-based RSUs 44 $ 100.41 Operating performance-based RSUs 44 $ 96.59 Stock-based incentive plans compensation expense is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Service-based restricted stock units (“RSUs”) $ 3,583 $ 3,368 $ 10,428 $ 8,158 Service-based stock appreciation rights (“SARs”) 2,896 2,491 7,804 6,514 Market performance-based restricted stock units 757 509 2,146 1,814 Operating performance-based restricted stock units 983 909 2,752 2,941 Employee stock purchase plan 312 — 997 — Total stock-based compensation expense $ 8,531 $ 7,277 $ 24,127 $ 19,427

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income Per Share	Reconciliation of the shares used in the basic and diluted earnings per share computations for the three and nine months ended September 30, 2019 and 2018 are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Basic weighted average shares outstanding 48,395 48,637 48,329 48,484 Add effects of share-based compensation instruments (1) 425 — — 943 Diluted weighted average shares outstanding 48,820 48,637 48,329 49,427 (1) Excluded from the computation of diluted earnings per share were stock options, SARs and restricted share units totaling 1.4 million and 2.8 million for the three months ended September 30, 2019 and 2018 , respectively, and 3.1 million and 0.5 million for the nine months ended September 30, 2019 and 2018 , respectively, because to include them would have been anti-dilutive under the treasury stock method.

Geographic and Segment Inform_2

Geographic and Segment Information (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Revenue from External Customers by Geographic Areas	The table below presents net sales by operating segment and geographic region (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Cardiopulmonary United States $ 39,054 $ 40,396 $ 119,580 $ 120,980 Europe 30,052 32,186 99,933 104,972 Rest of world 50,908 55,358 152,650 163,757 120,014 127,940 372,163 389,709 Heart Valves United States 4,626 6,145 13,660 18,828 Europe 9,572 9,421 30,757 33,400 Rest of world 14,679 16,980 43,484 45,162 28,877 32,546 87,901 97,390 Advanced Circulatory Support United States 6,313 5,947 22,290 11,415 Europe 186 38 497 391 Rest of world 36 90 310 284 6,535 6,075 23,097 12,090 Cardiovascular United States 49,993 52,488 155,530 151,223 Europe 39,810 41,645 131,187 138,763 Rest of world 65,623 72,428 196,444 209,203 155,426 166,561 483,161 499,189 Neuromodulation United States 88,433 87,194 245,870 254,581 Europe 10,425 9,497 34,080 31,731 Rest of world 13,685 8,252 31,511 23,128 112,543 104,943 311,461 309,440 Other 641 578 1,958 1,349 Totals United States 138,426 139,682 401,400 405,804 Europe (1) 50,235 51,142 165,267 170,494 Rest of world 79,949 81,258 229,913 233,680 Total (2) $ 268,610 $ 272,082 $ 796,580 $ 809,978 (1) Europe sales include those countries in which we have a direct sales presence, whereas European countries in which we sell through distributors are included in Rest of world. (2) No single customer represented over 10% of our consolidated net sales. No country’s net sales exceeded 10% of our consolidated sales except for the U.S.
Schedule of Segment Reporting Information, by Segment	The table below presents a reconciliation of segment income from continuing operations to consolidated income from continuing operations before tax (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Operating Income (Loss) from Continuing Operations 2019 2018 2019 2018 Cardiovascular (1) $ 36,180 $ 9,783 $ 47,289 $ 36,378 Neuromodulation (2) 30,010 36,432 52,260 132,377 Other (21,869 ) (29,420 ) (75,845 ) (89,479 ) Total reportable segment income from continuing operations 44,321 16,795 23,704 79,276 Merger and integration expenses 6,716 12,659 14,345 20,028 Restructuring expenses 698 436 4,563 2,793 Amortization of intangibles 11,146 9,457 29,690 28,075 Operating income (loss) from continuing operations 25,761 (5,757 ) (24,894 ) 28,380 Interest income 151 184 624 863 Interest expense (4,774 ) (2,633 ) (10,490 ) (7,750 ) Gain on acquisition — — — 11,484 Foreign exchange and other gains (losses) 327 (727 ) (795 ) (1,070 ) Income (loss) from continuing operations before tax $ 21,465 $ (8,933 ) $ (35,555 ) $ 31,907 (1) Results for the three and nine months ended September 30, 2019 include an insurance recovery of $33.8 million . Refer to “ Note 12. Commitments and Contingencies ” for additional information. (2) Results for the nine months ended September 30, 2019 include the impairment of intangible assets of $50.3 million . Assets by reportable segment are as follows (in thousands): Assets September 30, 2019 December 31, 2018 Cardiovascular $ 1,511,639 $ 1,532,825 Neuromodulation 696,666 731,840 Other 301,636 285,036 Total assets $ 2,509,941 $ 2,549,701 Capital expenditures by segment are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Capital expenditures 2019 2018 2019 2018 Cardiovascular $ 5,178 $ 8,032 $ 13,564 $ 15,757 Neuromodulation 136 512 666 1,359 Other 691 4,359 2,571 7,058 Discontinued operations — — — 925 Total $ 6,005 $ 12,903 $ 16,801 $ 25,099
Schedule of Goodwill	The changes in the carrying amount of goodwill by reportable segment for the nine months ended September 30, 2019 were as follows (in thousands): Neuromodulation Cardiovascular Other Total December 31, 2018 $ 398,539 $ 515,859 $ 42,417 $ 956,815 Goodwill as a result of acquisitions — 1,550 — 1,550 Measurement period adjustments — (3,326 ) — (3,326 ) Foreign currency adjustments 215 (9,710 ) — (9,495 ) September 30, 2019 $ 398,754 $ 504,373 $ 42,417 $ 945,544
Long-lived Assets by Geographic Areas	Property, plant and equipment, net by geography are as follows (in thousands): PP&E September 30, 2019 December 31, 2018 United States $ 63,473 $ 68,862 Europe 106,066 112,376 Rest of world 9,968 10,162 Total $ 179,507 $ 191,400

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	9 Months Ended
	Sep. 30, 2019
Balance Sheet Related Disclosures [Abstract]
Inventories	Inventories consisted of the following (in thousands): September 30, 2019 December 31, 2018 Raw materials $ 45,239 $ 40,387 Work-in-process 18,245 15,999 Finished goods 104,272 97,149 $ 167,756 $ 153,535
Accrued Liabilities	Accrued liabilities and other consisted of the following (in thousands): September 30, 2019 December 31, 2018 Contingent consideration (1) $ 24,802 $ 18,530 CRM purchase price adjustment payable to MicroPort Scientific Corporation 14,891 14,891 Legal and administrative costs 13,200 9,189 Operating lease liabilities (2) 10,565 — Product remediation (3) 7,444 13,945 Contract liabilities 5,628 3,304 Research and development costs 5,109 1,841 Provisions for agents, returns and other 4,038 4,934 Restructuring related liabilities (4) 2,621 9,393 Derivative contract liabilities (5) 3,455 5,063 Other amounts payable to MicroPort Scientific Corporation 852 9,319 Other accrued expenses 35,851 33,876 $ 128,456 $ 124,285 (1) Refer to “ Note 8. Fair Value Measurements ” (2) Refer to “ Note 11. Leases ” (3) Refer to “ Note 5. Product Remediation Liability ” (4) Refer to “ Note 4. Restructuring ” (5) Refer to “ Note 10. Derivatives and Risk Management ”

New Accounting Pronouncements (

New Accounting Pronouncements (Tables)	9 Months Ended
	Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	The following table provides a description of our adoption of new Accounting Standards Updates (“ASUs”) issued by the FASB and the impact of the adoption on our condensed financial statements: Issue Date & Standard Description Date of Adoption Effect on Financial Statements or Other Significant Matters February 2016 ASU No. 2016-02, Leases (Topic 842) and subsequent amendments The standard requires lessees to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use (“ROU”) assets and to provide enhanced disclosures. Furthermore, from a lessor perspective, certain of our agreements that allow the customer to use, rather than purchase, our medical devices met the criteria of being a lease in accordance with the new standard. January 1, 2019 Adoption of the new standard resulted in the recognition of ROU assets and lease liabilities of approximately $60 million as of January 1, 2019. Refer to “Note 11. Leases.” June 2018 ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting This update simplifies the accounting for non-employee share-based payment transactions. January 1, 2019 There was no material impact to our condensed consolidated financial statements as a result of adopting this ASU. The following table provides a description of future adoptions of new accounting standards that may have an impact on our financial statements when adopted: Issue Date & Standard Description Projected Date of Adoption Effect on Financial Statements or Other Significant Matters June 2016 ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326) The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The modified-retrospective approach is generally applicable through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Early adoption is permitted. January 1, 2020 We are currently evaluating the effect this standard will have on our condensed consolidated financial statements and related disclosures. January 2017 ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment This update removes step 2 of the goodwill impairment test that compares the implied fair value of goodwill with its carrying amount. Instead, an impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge will be recorded by the amount a reporting unit’s carrying amount exceeds its fair value. Early adoption is permitted. January 1, 2020 We are currently evaluating the effect this standard will have on our condensed consolidated financial statements and related disclosures. August 2018 ASU No. 2018-13, Fair Value Measurement (Topic 820): Changes to the Disclosure Requirements for Fair Value Measurement This update removes, modifies and adds certain disclosure requirements related to fair value measurements. Early adoption is permitted. January 1, 2020 We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statement disclosures. August 2018 ASU No. 2018-14, Compensation—Retirement Benefits—Defined Benefit Plans—General (Subtopic 715-20): Changes to the Disclosure Requirements for Defined Benefit Plans This update adds and removes certain disclosure requirements related to defined benefit plans. This ASU is to be implemented on a retrospective basis for all periods presented with early adoption permitted. January 1, 2021 We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statement disclosures. August 2018 ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract This update clarifies and aligns the accounting for implementation costs for hosting arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is to be applied either retrospectively or prospectively with early adoption permitted. January 1, 2020 We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statements.

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Financial Statements (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Short-term Debt [Line Items]
Amortization of intangibles	$ 11,146	$ 9,457	$ 29,690	$ 28,075
Incorrectly Excluded From Cost Of Sales | Cost of Sales
Short-term Debt [Line Items]
Amortization of intangibles				$ 10,700

Business Combinations (Details)

Business Combinations (Details) - USD ($) $ in Thousands	Jun. 12, 2019	Sep. 30, 2019
Business Acquisition [Line Items]
Goodwill, Acquired During Period		$ 1,550
Miami Instruments
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	$ 17,000
Business Combination, Upfront Costs	10,800
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	6,000
Goodwill, Acquired During Period	1,500
Developed Technology Rights and In Process Research and Development [Member] | Miami Instruments
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	$ 14,700

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	Apr. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital expenditures		$ 6,005	$ 12,903	$ 16,801	$ 25,099
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital expenditures		0	0	0	925
CRM Business Franchise
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred	$ 195,900
Consideration transferred, cash	$ 9,200
Transition services		$ 100	1,100	$ 900	$ 2,000
Stock-based compensation			2,100
CRM Business Franchise | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital expenditures			$ 900

Discontinued Operations (Operat

Discontinued Operations (Operating Gains and Losses) (Details) - CRM Business Franchise - Discontinued Operations, Held-for-sale - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	$ 0	$ 0	$ 0	$ 77,366
Costs and expenses:
Cost of sales	0	0	(43)	27,306
Selling, general and administrative expenses	0	543	26	43,441
Research and development	0	0	(161)	16,577
Restructuring expenses	0	0	0	651
Revaluation gain on assets and liabilities held for sale	0	0	0	(1,213)
Loss on sale of CRM	0	0	0	214
Operating (loss) income from discontinued operations	0	(543)	178	(9,610)
Foreign exchange and other gains	0	0	0	102
(Loss) income from discontinued operations, before tax	0	(543)	178	(9,508)
Income tax expense (benefit)	0	361	0	(804)
Losses from equity method investments	0	0	0	(1,211)
Net (loss) income from discontinued operations	$ 0	$ (904)	$ 178	$ (9,915)

Restructuring (Narrative) (Deta

Restructuring (Narrative) (Details)	9 Months Ended
	Sep. 30, 2019employee
2018 Reorganization Plan | Cardiovascular
Restructuring Cost and Reserve [Line Items]
Expected number of positions eliminated	75

Restructuring (Restructuring an

Restructuring (Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Restructuring Reserve [Roll Forward]
Charges	$ 698	$ 436	$ 4,563	$ 2,793
Reorganization Plans
Restructuring Reserve [Roll Forward]
Beginning liability balance			13,264
Charges			4,563
Cash payments and other			(15,206)
Ending liability balance	2,621		2,621
Restructuring costs incurred to date	103,800		103,800
Reorganization Plans | Employee Severance and Other Termination Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance			10,195
Charges			4,488
Cash payments and other			(13,147)
Ending liability balance	1,536		1,536
Reorganization Plans | Other
Restructuring Reserve [Roll Forward]
Beginning liability balance			3,069
Charges			75
Cash payments and other			(2,059)
Ending liability balance	$ 1,085		$ 1,085

Restructuring (Restructuring Ex

Restructuring (Restructuring Expense by Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Charges	$ 698	$ 436	$ 4,563	$ 2,793
Operating Segments | Cardiovascular
Restructuring Cost and Reserve [Line Items]
Charges	783	354	1,521	2,093
Operating Segments | Neuromodulation
Restructuring Cost and Reserve [Line Items]
Charges	(171)	17	314	34
Other
Restructuring Cost and Reserve [Line Items]
Charges	$ 86	$ 65	$ 2,728	$ 666

Product Remediation Liability_2

Product Remediation Liability (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Accrual for Environmental Loss Contingencies [Roll Forward]
Product remediation, beginning			$ 14,745
Adjustments			2,567
Remediation activity			(9,341)
Effect of changes in foreign currency exchange rates			(527)
Product remediation, ending	$ 7,444		7,444
Product remediation expense	3,076	$ 3,434	11,136	$ 8,691
Product Liability
Product Liability Contingency [Line Items]
Litigation provision liability	$ 152,968		$ 152,968		$ 294,061

Intangible Assets - Indefinite-

Intangible Assets - Indefinite-lived Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 0	$ 0	$ 50,295	$ 0
In Process Research and Development
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets	50,300
Indefinite-lived intangible assets	112,000		$ 112,000
Scenario, Adjustment
Indefinite-lived Intangible Assets [Line Items]
Decrease in intangible assets	$ 107,500

Intangible Assets - Finite-live

Intangible Assets - Finite-lived Intangible Assets (Details) - Developed Technology $ in Millions	3 Months Ended
	Sep. 30, 2019USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	15 years
Scenario, Adjustment
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 107.5

Investments (Details)

Investments (Details) $ in Thousands, € in Millions	3 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019EUR (€)	Dec. 31, 2018USD ($)
Schedule of Equity Method Investments [Line Items]
Investments	$ 24,667		$ 24,823
Equity method investments	275		0
Total investments	24,942		24,823
Payment to acquire Investments	5,500	€ 5
Cost Method Investee | Respicardia Inc. | Prepaid expenses and other current assets
Schedule of Equity Method Investments [Line Items]
Outstanding loans	600		600
Respicardia Inc.
Schedule of Equity Method Investments [Line Items]
Investments	17,706		17,706
Ceribell, Inc.
Schedule of Equity Method Investments [Line Items]
Investments	3,000		3,000
Rainbow Medical Ltd.
Schedule of Equity Method Investments [Line Items]
Investments	1,067		1,119
MD Start II
Schedule of Equity Method Investments [Line Items]
Investments	1,090		1,144
Highlife S.A.S.
Schedule of Equity Method Investments [Line Items]
Investments	1,034		1,084
Other
Schedule of Equity Method Investments [Line Items]
Investments	$ 770		$ 770

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)acquisition	Dec. 31, 2018USD ($)
Liabilities:
Number of businesses acquired | acquisition	5
Fair Value, Recurring
Assets:
Total assets	$ 1,213	$ 236
Liabilities:
Contingent consideration	165,274	179,911
Total liabilities	169,120	185,303
Fair Value, Recurring | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Liabilities:
Derivative liabilities	1,458	1,354
Fair Value, Recurring | Derivatives Designated as Hedging Instruments | Interest Rate Contract
Liabilities:
Derivative liabilities	519	865
Fair Value, Recurring | Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative asset	1,213	236
Liabilities:
Derivative liabilities	1,869	3,173
Fair Value, Recurring | Level 1
Assets:
Total assets	0	0
Liabilities:
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Recurring | Level 1 | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 1 | Derivatives Designated as Hedging Instruments | Interest Rate Contract
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 1 | Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative asset	0	0
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 2
Assets:
Total assets	1,213	236
Liabilities:
Contingent consideration	0	0
Total liabilities	3,846	5,392
Fair Value, Recurring | Level 2 | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Liabilities:
Derivative liabilities	1,458	1,354
Fair Value, Recurring | Level 2 | Derivatives Designated as Hedging Instruments | Interest Rate Contract
Liabilities:
Derivative liabilities	519	865
Fair Value, Recurring | Level 2 | Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative asset	1,213	236
Liabilities:
Derivative liabilities	1,869	3,173
Fair Value, Recurring | Level 3
Assets:
Total assets	0	0
Liabilities:
Contingent consideration	165,274	179,911
Total liabilities	165,274	179,911
Fair Value, Recurring | Level 3 | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 3 | Derivatives Designated as Hedging Instruments | Interest Rate Contract
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 3 | Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative asset	0	0
Liabilities:
Derivative liabilities	$ 0	$ 0

Fair Value Measurements (Contin

Fair Value Measurements (Contingent Consideration Reconciliation) (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Jul. 31, 2019	Sep. 30, 2019
ImThera Medical, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Payments	$ 19,000
Cost of sales - exclusive of amortization
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Interest rate changes		$ (900)
Research and development
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Interest rate changes		(1,500)
Level 3 | ImThera Medical, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Timing delay of anticipated regulatory approval, amount		17,800
Fair Value, Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Total contingent consideration liability at December 31, 2018		179,911
Total contingent consideration liability at September 30, 2019		165,274
Fair Value, Recurring | Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Total contingent consideration liability at December 31, 2018		179,911
Additions		7,184
Payments		(19,234)
Changes in fair value		(2,425)
Effect of changes in foreign currency exchange rates		(162)
Total contingent consideration liability at September 30, 2019		165,274
Less current portion of contingent consideration liability at September 30, 2019		24,802
Long-term portion of contingent consideration liability at September 30, 2019		$ 140,472

Financing Arrangements (Schedul

Financing Arrangements (Schedule of Debt) (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total long-term facilities	$ 338,571,000	$ 162,841,000
Less current portion of long-term debt	65,684,000	23,303,000
Total long-term debt	272,887,000	139,538,000
Letter of credit | 2019 Debt Facility
Debt Instrument [Line Items]
Finance contract, borrowing base	350,000,000
Loans Payable | 2019 Debt Facility
Debt Instrument [Line Items]
Total long-term facilities	$ 182,434,000	0
Semi-annual periodic payment, as a percentage of principal	20.00%
Loans Payable | 2019 Debt Facility | Minimum
Debt Instrument [Line Items]
Interest rate (percent)	1.40%
Loans Payable | 2019 Debt Facility | Maximum
Debt Instrument [Line Items]
Interest rate (percent)	3.72%
Loans Payable | 2017 European Investment Bank
Debt Instrument [Line Items]
Total long-term facilities	$ 103,570,000	103,570,000
Loans Payable | 2017 European Investment Bank | Minimum
Debt Instrument [Line Items]
Interest rate (percent)	3.47%
Loans Payable | 2017 European Investment Bank | Maximum
Debt Instrument [Line Items]
Interest rate (percent)	3.53%
Loans Payable | 2014 European Investment Bank
Debt Instrument [Line Items]
Total long-term facilities	$ 36,317,000	47,606,000
Interest rate (percent)	0.98%
Loans Payable | Mediocredito Italiano
Debt Instrument [Line Items]
Total long-term facilities	$ 6,674,000	7,623,000
Loans Payable | Mediocredito Italiano | Minimum
Debt Instrument [Line Items]
Interest rate (percent)	0.50%
Loans Payable | Mediocredito Italiano | Maximum
Debt Instrument [Line Items]
Interest rate (percent)	2.86%
Loans Payable | Bank of America Merrill Lynch Banco Múltiplo S.A.
Debt Instrument [Line Items]
Total long-term facilities	$ 4,898,000	0
Interest rate (percent)	8.47%
Loans Payable | Bank of America, U.S.
Debt Instrument [Line Items]
Total long-term facilities	$ 1,999,000	0
Interest rate (percent)	4.51%
Loans Payable | Banca del Mezzogiorno
Debt Instrument [Line Items]
Total long-term facilities	$ 1,304,000	2,718,000
Loans Payable | Banca del Mezzogiorno | Minimum
Debt Instrument [Line Items]
Interest rate (percent)	0.50%
Loans Payable | Banca del Mezzogiorno | Maximum
Debt Instrument [Line Items]
Interest rate (percent)	2.91%
Other
Debt Instrument [Line Items]
Total long-term facilities	$ 1,375,000	$ 1,324,000

Financing Arrangements (Narrati

Financing Arrangements (Narrative) (Details)	Jul. 25, 2019USD ($)	Sep. 30, 2019USD ($)	Jul. 25, 2019EUR (€)	Dec. 31, 2018USD ($)
Revolving Credit Facility
Debt Instrument [Line Items]
Short-term debt		$ 3,100,000		$ 5,500,000
Minimum | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term		10 days
Interest rate (percent)		8.50%
Maximum | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term		210 days
Interest rate (percent)		8.69%
US Denominated Borrowings | London Interbank Offered Rate (LIBOR) | Multicurrency Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.60%
Euro Denominated Borrowings | London Interbank Offered Rate (LIBOR) | Multicurrency Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.40%
Banca Nazionale del Lavoro SpA
Debt Instrument [Line Items]
Finance contract, borrowing base	$ 43,600,000		€ 40,000,000
Line of credit		$ 0
Debt instrument, term	2 years
Banca Nazionale del Lavoro SpA | Euro Interbank Offered Rate (EURIBOR) | Multicurrency Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.80%
Letter of credit | 2019 Debt Facility
Debt Instrument [Line Items]
Finance contract, borrowing base		$ 350,000,000
Loans Payable | 2019 Debt Facility
Debt Instrument [Line Items]
Semi-annual periodic payment, as a percentage of principal		20.00%
Loans Payable | 2019 Debt Facility | Minimum
Debt Instrument [Line Items]
Interest rate (percent)		1.40%
Loans Payable | 2019 Debt Facility | Maximum
Debt Instrument [Line Items]
Interest rate (percent)		3.72%

Derivatives and Risk Manageme_3

Derivatives and Risk Management (Narrative) (Details) - Derivatives Not Designated as Hedging Instruments - Foreign Exchange Contract - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Derivative [Line Items]
Notional amount	$ 273.1		$ 273.1		$ 320.2
Foreign exchange and other (losses) gains
Derivative [Line Items]
Gain (loss) on derivative	$ 3.1	$ 5.6	$ 6.8	$ (6)

Derivatives and Risk Manageme_4

Derivatives and Risk Management (Derivative Notional Amounts) (Details) - Derivatives Designated as Hedging Instruments - Cash Flow Hedging - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Derivative [Line Items]
Notional amount	$ 94,814	$ 109,134
After-Tax Net Loss in AOCI as of Period End	(1,450)
Amount Expected to be Reclassified to Earnings in Next 12 Months	(1,391)
Foreign Exchange Contract
Derivative [Line Items]
After-Tax Net Loss in AOCI as of Period End	(1,313)
Amount Expected to be Reclassified to Earnings in Next 12 Months	(1,313)
Foreign Exchange Contract | United Kingdom, Pounds
Derivative [Line Items]
Notional amount	8,185	9,629
Foreign Exchange Contract | Japan, Yen
Derivative [Line Items]
Notional amount	26,462	23,985
Foreign Exchange Contract | Canada, Dollars
Derivative [Line Items]
Notional amount	1,532	7,637
Foreign Exchange Contract | Euro Member Countries, Euro
Derivative [Line Items]
Notional amount	29,563	29,768
Interest Rate Swap Contracts
Derivative [Line Items]
Notional amount	29,072	$ 38,115
After-Tax Net Loss in AOCI as of Period End	(137)
Amount Expected to be Reclassified to Earnings in Next 12 Months	$ (78)

Derivatives and Risk Manageme_5

Derivatives and Risk Management (Amount of Gain (Loss) Recognized in OCI and Income Statement) (Details) - Cash Flow Hedging - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Losses Recognized in OCI	$ (689)		$ 933
Gains (Losses) Reclassified from AOCI to Earnings	181		1,598
Gains Recognized in OCI		$ 125		$ 314
Gains (Losses) Reclassified from AOCI to Earnings		(568)		77
Foreign Exchange Contract | Foreign exchange and other (losses) gains
Derivative Instruments, Gain (Loss) [Line Items]
Losses Recognized in OCI	(689)		933
Gains (Losses) Reclassified from AOCI to Earnings	963		3,094
Gains Recognized in OCI		125		314
Gains (Losses) Reclassified from AOCI to Earnings		2,511		1,999
Foreign Exchange Contract | SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Losses Recognized in OCI	0		0
Gains (Losses) Reclassified from AOCI to Earnings	(742)		(1,470)
Gains Recognized in OCI		0		0
Gains (Losses) Reclassified from AOCI to Earnings		(3,007)		(1,833)
Interest Rate Swap Contracts | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Losses Recognized in OCI	0		0
Gains (Losses) Reclassified from AOCI to Earnings	$ (40)		$ (26)
Gains Recognized in OCI		0		0
Gains (Losses) Reclassified from AOCI to Earnings		$ (72)		$ (89)

Derivatives and Risk Manageme_6

Derivatives and Risk Management (Fair Value of Derivative Instruments) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Total asset derivatives	$ 1,213	$ 236
Total liability derivatives	3,846	5,392
Derivatives Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Total liability derivatives	1,977	2,219
Derivatives Designated as Hedging Instruments | Prepaid expenses and other current assets | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total liability derivatives	1,201
Derivatives Designated as Hedging Instruments | Accrued liabilities | Interest Rate Contract
Derivatives, Fair Value [Line Items]
Total liability derivatives	385	536
Derivatives Designated as Hedging Instruments | Accrued liabilities | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total liability derivatives	257	1,354
Derivatives Designated as Hedging Instruments | Other long-term liabilities | Interest Rate Contract
Derivatives, Fair Value [Line Items]
Total liability derivatives	134	329
Derivatives Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Total asset derivatives	1,213	236
Total liability derivatives	1,869	3,173
Derivatives Not Designated as Hedging Instruments | Prepaid expenses and other current assets | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total asset derivatives	1,213	236
Derivatives Not Designated as Hedging Instruments | Accrued liabilities | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total liability derivatives	$ 1,869	$ 3,173

Leases - Components Of Operatin

Leases - Components Of Operating Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Leases [Abstract]
Lessee, operating lease, renewal term	12 years
Assets
Operating lease right-of-use assets	$ 54,283
Liabilities
Accrued liabilities and other	10,565	$ 0
Long-term operating lease liabilities (Note 11)	44,724	$ 0
Total lease liabilities	$ 55,289

Leases - Costs (Details)

Leases - Costs (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 3,391	$ 10,600
Variable lease cost	225	651
Short-term lease cost	258	538
Lease, Cost	$ 3,874	$ 11,789

Leases - Contractual Maturities

Leases - Contractual Maturities (Details) $ in Thousands	Sep. 30, 2019USD ($)
Leases [Abstract]
2019	$ 2,728
2020	11,309
2021	9,411
2022	8,263
2023	6,913
Thereafter	21,866
Total lease payments	60,490
Less: Amount representing interest	5,201
Present value of lease liabilities	$ 55,289

Leases - Lease Term and Discoun

Leases - Lease Term and Discount Rate (Details)	Sep. 30, 2019
Leases [Abstract]
Weighted Average Remaining Lease Term (in years)	7 years 3 months 18 days
Weighted Average Discount Rate	2.30%

Leases - Cash Flow (Details)

Leases - Cash Flow (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 10,111
Operating lease assets obtained in exchange for lease liabilities	$ 5,403

Leases - Future Minimum Operati

Leases - Future Minimum Operating Lease Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
Leases [Abstract]
Less than one year	$ 11,986
One to three years	21,031
Three to five years	14,998
Thereafter	20,943
Total	$ 68,958

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) € in Thousands, $ in Thousands	May 15, 2018EUR (€)	Apr. 01, 2016USD ($)	Jul. 31, 2019USD ($)	Oct. 31, 2016EUR (€)	Jan. 31, 2004USD ($)	Sep. 30, 2019USD ($)installmentnotice	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)installmentnotice	Sep. 30, 2018USD ($)	Oct. 29, 2019claim	Sep. 30, 2019EUR (€)installmentnotice	May 31, 2019EUR (€)	Dec. 31, 2018USD ($)	Aug. 27, 2015non-conformity	Oct. 30, 2009EUR (€)
Other Commitments [Line Items]
Product remediation						$ 7,444		$ 7,444					$ 14,745
Insurance recoveries						33,834	$ 0	33,834	$ 0
Unrecognized tax benefits, net of settlement payment						16,800		16,800			€ 15,400
Regional Internal Revenue Office of Lombardy
Other Commitments [Line Items]
Application pending approval, payments for legal settlements | €												€ 1,900
Settled Litigation
Other Commitments [Line Items]
Litigation settlement				€ 400		436
Legal fees	€ 84					92
Threatened Litigation | Regional Internal Revenue Office of Lombardy
Other Commitments [Line Items]
Losses under dispute						$ 68,200		$ 68,200			€ 62,600
Number of equal installments | installment						5		5			5
Number of notice of assessments | notice						3		3			3
FDA Warning Letter
Other Commitments [Line Items]
Number of observed non-conformities | non-conformity														2
Product Liability
Other Commitments [Line Items]
Litigation settlement, amount awarded to other party								$ 225,000
Payments for legal settlements			$ 135,000
Insurance recoveries			$ 33,800			$ 33,800		33,800
Litigation provision liability						152,968		152,968					$ 294,061
SNIA | Pending Litigation | SNIA s.p.a
Other Commitments [Line Items]
Compensation sought					$ 4,000,000
SNIA | Settled Litigation | Sorin S.p.A. | Positive Outcome of Litigation
Other Commitments [Line Items]
Litigation settlement		$ 318
Tax Years 2002 - 2006 | Threatened Litigation | Regional Internal Revenue Office of Lombardy
Other Commitments [Line Items]
Losses under dispute						$ 111,900		$ 111,900							€ 102,600
Subsequent Event | Product Liability
Other Commitments [Line Items]
Pending claims, number | claim										100

Commitments and Contingencies_2

Commitments and Contingencies (Schedule of Product Liability) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Litigation Provision Liability
Less current portion of litigation provision liability at September 30, 2019	$ 121,468	$ 161,851
Long-term portion of litigation provision liability at September 30, 2019	31,500
Product Liability
Litigation Provision Liability
Total litigation provision liability at December 31, 2018	294,061
Payments	(140,823)
FX and other	(270)
Total litigation provision liability at September 30, 2019	$ 152,968

Stockholders' Equity Statement

Stockholders' Equity Statement of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2018
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)			49,323,418
Beginning Balance	$ 1,483,328	$ 1,783,034	$ 1,503,738	$ 1,815,314
Adoption of ASU No. 2016-16					$ (22,430)
Share issuances				0
Stock-based compensation plans	8,272	6,747	20,624	16,504
Net income (loss)	32,118	(7,177)	(11,946)	21,162
Other comprehensive income (loss)	$ (28,436)	2,388	$ (17,134)	(45,558)
Ending Balance (in shares)	49,380,570		49,380,570
Ending Balance	$ 1,495,282	$ 1,784,992	$ 1,495,282	$ 1,784,992
Ordinary Shares
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)	49,380,000	48,661,000	49,323,000	48,290,000
Beginning Balance	$ 76,217	$ 75,269	$ 76,144	$ 74,750
Share issuances (in shares)				300,000
Share issuances				$ 422
Stock-based compensation plans (in shares)	1,000	33,000	58,000	104,000
Stock-based compensation plans	$ 0	$ 42	$ 73	$ 139
Ending Balance (in shares)	49,381,000	48,694,000	49,381,000	48,694,000
Ending Balance	$ 76,217	$ 75,311	$ 76,217	$ 75,311
Additional Paid-In Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	1,717,220	1,744,262	1,705,111	1,735,048
Stock-based compensation plans	8,262	6,624	20,371	15,838
Ending Balance	1,725,482	1,750,886	1,725,482	1,750,886
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(1,292)	(109)	(1,462)	(133)
Share issuances				(422)
Stock-based compensation plans	10	81	180	527
Ending Balance	(1,282)	(28)	(1,282)	(28)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(13,174)	(2,633)	(24,476)	45,313
Other comprehensive income (loss)	(28,436)		(17,134)	(45,558)
Ending Balance	(41,610)	(245)	(41,610)	(245)
Retained Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(295,643)	(33,755)	(251,579)	(39,664)
Adoption of ASU No. 2016-16					$ (22,430)
Net income (loss)	32,118	(7,177)	(11,946)	21,162
Ending Balance	$ (263,525)	$ (40,932)	$ (263,525)	$ (40,932)

Stockholders' Equity (Comprehen

Stockholders' Equity (Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	$ 1,483,328	$ 1,783,034	$ 1,503,738	$ 1,815,314
Other comprehensive income (loss) before reclassifications, before tax			(15,695)	(36,413)
Tax expense			(224)	(75)
Other comprehensive income (loss) before reclassifications, net of tax			(15,919)	(36,488)
Reclassification of gain from accumulated other comprehensive income (loss), before tax			(1,598)	(9,088)
Reclassification of tax expense			383	18
Reclassification of gain from accumulated other comprehensive income (loss), after tax			(1,215)	(9,070)
Total other comprehensive (loss) income	(28,436)	2,388	(17,134)	(45,558)
Ending Balance	1,495,282	1,784,992	1,495,282	1,784,992
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(13,174)	(2,633)	(24,476)	45,313
Total other comprehensive (loss) income	(28,436)		(17,134)	(45,558)
Ending Balance	(41,610)	(245)	(41,610)	(245)
Change in Unrealized Gain (Loss) on Derivatives
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance			(944)	(919)
Other comprehensive income (loss) before reclassifications, before tax			933	314
Tax expense			(224)	(75)
Other comprehensive income (loss) before reclassifications, net of tax			709	239
Reclassification of gain from accumulated other comprehensive income (loss), before tax			(1,598)	(77)
Reclassification of tax expense			383	18
Reclassification of gain from accumulated other comprehensive income (loss), after tax			(1,215)	(59)
Total other comprehensive (loss) income			(506)	180
Ending Balance	(1,450)	(739)	(1,450)	(739)
Foreign Currency Translation Adjustments Gain (Loss)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance			(23,532)	46,232
Other comprehensive income (loss) before reclassifications, before tax			(16,628)	(36,727)
Tax expense			0	0
Other comprehensive income (loss) before reclassifications, net of tax			(16,628)	(36,727)
Reclassification of gain from accumulated other comprehensive income (loss), before tax			0	(9,011)
Reclassification of tax expense			0	0
Reclassification of gain from accumulated other comprehensive income (loss), after tax			0	(9,011)
Total other comprehensive (loss) income			(16,628)	(45,738)
Ending Balance	$ (40,160)	$ 494	$ (40,160)	$ 494

Stock-Based Incentive Plan (Com

Stock-Based Incentive Plan (Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 8,531	$ 7,277	$ 24,127	$ 19,427
Share-based compensation arrangement, vesting period			4 years
Share-based compensation arrangement, compensation cost	3,600		$ 6,800
Service-based restricted stock units (“RSUs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3,583	3,368	10,428	8,158
Service-based stock appreciation rights (“SARs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,896	2,491	7,804	6,514
Market performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	757	509	$ 2,146	1,814
Share-based compensation arrangement, vesting period			3 years
Operating performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	983	909	$ 2,752	2,941
Share-based compensation arrangement, vesting period			3 years
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 312	$ 0	$ 997	$ 0

Stock-Based Incentive Plan (Exe

Stock-Based Incentive Plan (Executed Agreements) (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Service-based stock appreciation rights (“SARs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	592
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 31.22
Service-based restricted stock units (“RSUs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	286
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 93.03
Market performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	44
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 100.41
Operating performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	44
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 96.59

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Effective tax rate (percent)	(49.60%)	29.80%	65.90%	0.60%
Unrecognized tax benefits	$ 16.6		$ 16.6		$ 22.9
Unrecognized tax benefits, potential decrease amount	$ 1.3		$ 1.3

Net Income Per Share (Schedule

Net Income Per Share (Schedule of Earnings Per Share, Basic and Diluted) (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Basic weighted average shares outstanding (in shares)	48,395	48,637	48,329	48,484
Add effects of share-based compensation instruments (in shares)	425	0	0	943
Diluted weighted average shares outstanding (in shares)	48,820	48,637	48,329	49,427

Net Income Per Share (Narrative

Net Income Per Share (Narrative of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	1.4	2.8	3.1	0.5

Geographic and Segment Inform_3

Geographic and Segment Information (Segment Info) (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2019USD ($)	Sep. 30, 2019USD ($)geographic_region	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)segmentgeographic_region	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Segment Reporting Information [Line Items]
Reportable segments | segment				2
Number of geographic regions in which entity operates | geographic_region		3		3
Net sales		$ 268,610	$ 272,082	$ 796,580	$ 809,978
Total reportable segment income from continuing operations		44,321	16,795	23,704	79,276
Merger and integration expenses		6,716	12,659	14,345	20,028
Restructuring expenses		698	436	4,563	2,793
Amortization of intangibles		11,146	9,457	29,690	28,075
Operating income (loss) from continuing operations		25,761	(5,757)	(24,894)	28,380
Interest income		151	184	624	863
Interest expense		4,774	2,633	10,490	7,750
Gain on acquisition		0	0	0	11,484
Foreign exchange and other gains (losses)		327	(727)	(795)	(1,070)
Income (loss) from continuing operations before tax		21,465	(8,933)	(35,555)	31,907
Insurance recoveries		33,834	0	33,834	0
Impairment of intangible assets		0	0	50,295	0
Assets		2,509,941		2,509,941		$ 2,549,701
Capital expenditures		6,005	12,903	16,801	25,099
Operating Segments
Segment Reporting Information [Line Items]
Net sales		268,610	272,082	796,580	809,978
Operating Segments | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		155,426	166,561	483,161	499,189
Restructuring expenses		783	354	1,521	2,093
Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales		112,543	104,943	311,461	309,440
Restructuring expenses		(171)	17	314	34
Other
Segment Reporting Information [Line Items]
Restructuring expenses		86	65	2,728	666
Continuing Operations | Operating Segments | Cardiovascular
Segment Reporting Information [Line Items]
Total reportable segment income from continuing operations		36,180	9,783	47,289	36,378
Assets		1,511,639		1,511,639		1,532,825
Capital expenditures		5,178	8,032	13,564	15,757
Continuing Operations | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Total reportable segment income from continuing operations		30,010	36,432	52,260	132,377
Assets		696,666		696,666		731,840
Capital expenditures		136	512	666	1,359
Continuing Operations | Other
Segment Reporting Information [Line Items]
Total reportable segment income from continuing operations		(21,869)	(29,420)	(75,845)	(89,479)
Assets		301,636		301,636		$ 285,036
Capital expenditures		691	4,359	2,571	7,058
Discontinued Operations
Segment Reporting Information [Line Items]
Capital expenditures		0	0	0	925
United States | Operating Segments
Segment Reporting Information [Line Items]
Net sales		138,426	139,682	401,400	405,804
United States | Operating Segments | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		49,993	52,488	155,530	151,223
United States | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales		88,433	87,194	245,870	254,581
Europe | Operating Segments
Segment Reporting Information [Line Items]
Net sales		50,235	51,142	165,267	170,494
Europe | Operating Segments | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		39,810	41,645	131,187	138,763
Europe | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales		10,425	9,497	34,080	31,731
Rest of world | Operating Segments
Segment Reporting Information [Line Items]
Net sales		79,949	81,258	229,913	233,680
Rest of world | Operating Segments | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		65,623	72,428	196,444	209,203
Rest of world | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales		13,685	8,252	31,511	23,128
Rest of world | Other
Segment Reporting Information [Line Items]
Net sales		641	578	1,958	1,349
Cardiopulmonary | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		120,014	127,940	372,163	389,709
Cardiopulmonary | United States | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		39,054	40,396	119,580	120,980
Cardiopulmonary | Europe | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		30,052	32,186	99,933	104,972
Cardiopulmonary | Rest of world | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		50,908	55,358	152,650	163,757
Heart Valves | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		28,877	32,546	87,901	97,390
Heart Valves | United States | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		4,626	6,145	13,660	18,828
Heart Valves | Europe | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		9,572	9,421	30,757	33,400
Heart Valves | Rest of world | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		14,679	16,980	43,484	45,162
Advanced Circulatory Support | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		6,535	6,075	23,097	12,090
Advanced Circulatory Support | United States | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		6,313	5,947	22,290	11,415
Advanced Circulatory Support | Europe | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		186	38	497	391
Advanced Circulatory Support | Rest of world | Cardiovascular
Segment Reporting Information [Line Items]
Net sales		36	$ 90	310	$ 284
Product Liability
Segment Reporting Information [Line Items]
Insurance recoveries	$ 33,800	$ 33,800		$ 33,800

Geographic and Segment Inform_4

Geographic and Segment Information (Changes in Carrying Amount of Goodwill) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Goodwill [Roll Forward]
Goodwill, beginning	$ 956,815
Goodwill as a result of acquisitions	1,550
Measurement period adjustments	(3,326)
Foreign currency adjustments	(9,495)
Goodwill, ending	945,544
Operating Segments | Neuromodulation
Goodwill [Roll Forward]
Goodwill, beginning	398,539
Goodwill as a result of acquisitions	0
Measurement period adjustments	0
Foreign currency adjustments	215
Goodwill, ending	398,754
Operating Segments | Cardiovascular
Goodwill [Roll Forward]
Goodwill, beginning	515,859
Goodwill as a result of acquisitions	1,550
Measurement period adjustments	(3,326)
Foreign currency adjustments	(9,710)
Goodwill, ending	504,373
Other
Goodwill [Roll Forward]
Goodwill, beginning	42,417
Goodwill as a result of acquisitions	0
Measurement period adjustments	0
Foreign currency adjustments	0
Goodwill, ending	$ 42,417

Geographic and Segment Inform_5

Geographic and Segment Information (Geographic Areas) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 179,507	$ 191,400
United States
Segment Reporting Information [Line Items]
Property, plant and equipment, net	63,473	68,862
Europe
Segment Reporting Information [Line Items]
Property, plant and equipment, net	106,066	112,376
Rest of world
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 9,968	$ 10,162

Supplemental Financial Inform_3

Supplemental Financial Information (Summary of Inventory) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 45,239	$ 40,387
Work-in-process	18,245	15,999
Finished goods	104,272	97,149
Inventory, Net	167,756	153,535
Provision for obsolescence	$ 10,900	$ 11,600

Supplemental Financial Inform_4

Supplemental Financial Information (Summary of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Contingent consideration	$ 24,802	$ 18,530
CRM purchase price adjustment payable to MicroPort Scientific Corporation	14,891	14,891
Legal and administrative costs	13,200	9,189
Operating lease liabilities	10,565	0
Product remediation	7,444	13,945
Contract liabilities	5,628	3,304
Research and development costs	5,109	1,841
Provisions for agents, returns and other	4,038	4,934
Restructuring related liabilities	2,621	9,393
Derivative contract liabilities	3,455	5,063
Other amounts payable to MicroPort Scientific Corporation	852	9,319
Other accrued expenses	35,851	33,876
Accrued liabilities	128,456	124,285
Contract liability	$ 7,100	$ 4,800

New Accounting Pronouncements_2

New Accounting Pronouncements (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease assets (Note 11)	$ 54,283
Present value of lease liabilities	$ 55,289
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease assets (Note 11)		$ 60,000
Present value of lease liabilities		$ 60,000